Your SlideShare is downloading. ×

CURRICULUM VITAE

1,272

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,272
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. CURRICULUM VITAE David L. Vesely, M.D., Ph.D., F.A.C.P., F.A.C.E. Professor of Internal Medicine, Molecular Pharmacology and Physiology University of South Florida Health Sciences Center Tampa, Florida Service to America Career Achievement Medal – 2007 For discovery, characterization, demonstration of physiologic effects and mechanisms of action of three hormones which are beneficial for the treatment of congestive heart failure, renal failure and cancer. Medical School Address: Chief of Endocrinology, Diabetes and Metabolism Tampa V. A. Medical Center 13000 Bruce B. Downs Boulevard Tampa, Florida 33612 Telephone: Office (813) 972-7624, Home (813) 977-8776 Fax: (813) 972-7623 Academic and Administrative Experience: Associate Division Director and Associate Program Director of Endocrinology, Diabetes & Metabolism at University of South Florida Health Sciences Center, 2007-present. Directs Endocrinology Training Program at J. A. Haley Veterans Medical Center. Acting Associate Chief of Staff for Research and Development at the James A. Haley Veterans Medical Center and Acting Chief of Endocrinology, Diabetes and Metabolism, University of South Florida Medical School, 2004, 2006. In addition to Director, University of South Florida Cardiac Hormone Center (Tampa), and Chief of Endocrinology, Diabetes and Metabolism, James A. Haley Veterans Medical Center, Tampa, Florida. Director, University of South Florida Cardiac Hormone Center, 1999-present. University of South Florida, Tampa, Florida. This is a multidisciplinary center consisting of faculty from Biochemistry and Molecular Biology (Molecular Medicine), Internal Medicine, Obstetrics and Gynecology, Molecular Pharmacology and Physiology. Chief, Endocrinology, Diabetes & Metabolism, 1993-present. James A. Haley Veterans Affairs Medical Center, Tampa, Florida. Provides leadership and training of endocrinology fellows, medical residents and fourth year medical students at James A. Haley Veterans Hospital which has more ambulatory care visits than any other veterans
  • 2. David L. Vesely, M.D., Ph.D. 2 hospital in the United States (over 1,425,000 clinical visits per year). Professor of Medicine, 1989-present. University of South Florida Health Sciences Center and James A. Haley Veterans Affairs Medical Center, Tampa, Florida. As Attending Physician at Tampa General Hospital, James A. Haley Veterans Medical Center, and Moffitt Cancer Center Hospital, serve as the endocrinology consult physician and provide comprehensive medical care for fee for service, medicare, and managed care patients including faculty and indigent patients while at the same time providing teaching instruction for third year medical students, medical housestaff, and endocrinology fellows. Distinguished Visiting Professor (July-Dec. 1995). The Christchurch School of Medicine, Christchurch, New Zealand. A mini sabbatical to determine the molecular species of brain natriuretic peptide prohormone and its metabolically active peptides within the human heart and circulation. This was a collaborative investigation with the Endocrinology Research Group in Christchurch consisting of Eric Espiner, M.D., Tim Yandle, Ph.D., A. Mark Richards, M.D., and M. Gary Nicholls, M.D. Professor of Molecular Pharmacology and Physiology (In addition to Professor of Medicine), 1990-present. University of South Florida Health Sciences Center, Tampa, Florida. Directs the research training of graduate and postgraduate PhD and MD students. Professor of Medicine, 1983-1989. University of Arkansas for Medical Sciences and Chief of Endocrinology and Metabolism, John L. McClellan Veterans Hospital Little Rock, Arkansas. Provided leadership in the training of third year medical students, medical residents, and endocrine fellows while also serving as the primary care physician in treating fee for service patients and patients in the federal health care system. Senior Fogarty International Scholar and Professor of Medicine, 1984-1985. Institut National de la Sante et de la Recherche Medicale Faculte de Medicine (Pasteur) Nice, France. Senior Fogarty International Fellowship from United States' National Institutes of Health was utilized to share new technologies with investigators at the Diabetes Branch of the French National Institutes of Health while at the same time learned new molecular biology techniques from French investigators under the direction of Pierre Freychet, M.D. Associate Professor of Medicine, Acting Chief, Division of Endocrinology and Metabolism, 1979-1983. University of Arkansas for Medical Sciences Little Rock, Arkansas. Developed Endocrinology and Metabolism Division at the University from a one member division with no extramural grant funds into a division with five MD endocrinologists and two PhDs with over one million dollars in extramural grant support. Assistant Professor of Medicine, Acting Chief, Division of Endocrinology and Metabolsim, 1978-1979. University of Arkansas for Medical Sciences Little Rock, Arkansas. Assistant Professor of Medicine, Division of Endocrinology and Metabolism,
  • 3. David L. Vesely, M.D., Ph.D. 3 1977-1978. University of Miami School of Medicine Miami, Florida. Instructor in Medicine, Department of Medicine, Division of Endocrinology and Metabolism, 1976-1977. University of Miami School of Medicine Miami, Florida. Education: Creighton University. Omaha, Nebraska, Bachelor of Science Biology 1961-1964. Creighton University, School of Dentistry, Omaha, Nebraska, 1964-1967. Doctor of Medicine (MD), University of Arizona School of Medicine, Department of Medicine, Tucson, Arizona, 1968-1972. Doctor of Philosophy (PhD), University of Arizona, Department of Biological Sciences, Tucson, Arizona, 1968-1972. National Institutes of Health (N.I.H.) Fellow for combined medical and Ph.D. training, 1968-1972. Postgraduate Training: Internship, University of Miami Affiliated Hospitals (Straight Medical), Miami, Florida, 1972-1973. Residency, University of Miami Affiliated Hospitals (Straight Medical), Miami, Florida, 1973-1974. Fellowship in Endocrinology and Metabolism, Division of Endocrinology and Metabolism, University of Miami, School of Medicine, Miami, Florida,1974-1976. Personal: Born: March 6, 1943 Married: Clo Farrell, 1973 (deceased-cancer, December 2002) Children: Susanna, 1974; Catherine, 1978; Matthew, 1981; Brian, 1984; Jonathan, 1988.
  • 4. David L. Vesely, M.D., Ph.D. 4 Honors and Awards: President of Delta Sigma Delta, international dental fraternity, 1965-1967. President of Dental School Sodality, 1965-1967. National Institutes of Health Pre-Doctoral Fellow (Biochemistry and Physiology, University of Arizona, Tucson, Arizona), 1968-1972. Lange Scholarship Award, 1968-1972. Mosby Scholarship Award, 1968-1972. National Institutes of Health Post-Doctoral Fellow (Endocrinology Subspeciality Training and Research Fellowship, University of Miami School of Medicine. Miami, Florida), 1974-1976. Outstanding Clinical Teacher, University of Miami School of Medicine, 1977. Physician Recognition Award from American Medical Association, 1977. Outstanding Young Men of America Award for 1979 awarded by U.S. National Jaycees. New York Academy of Science, member, 1979. Who's Who in the South and Southwest, 1980 to present. Outstanding Clinical Teacher voted by the 1979-1980 Senior Medical Class, 1980. Invited participant in Gordon Research Conference on Cyclic Nucleotide Metabolism, 1981. Senior Fogarty International Fellow (N.I.H.) at Institut National de la Sante et de la Recherche Medicale. Nice, France, 1984-1985. Inducted into American Men and Women of Science for outstanding contributions to the biological sciences, 1986-1987. Outstanding Clinical Teacher voted by 1987-1988 Senior Medical Class, 1988. Distinguished Physicians of America Award, 1990. Native Son Award, 1990. City of Scribner (Nebraska) Award for outstanding achievements by a person whose early education began in Scribner. The Award plaque and portrait of Dr. Vesely will be permanently displayed in the Civic Auditorium. Dr. Vesely received the American Legion Medal as the Outstanding Scholar-Athlete when he graduated from Scribner Public High School in 1961. The Best of Who's Who in the Health and Medical Sciences, 1991 to present.
  • 5. David L. Vesely, M.D., Ph.D. 5 Honors and Awards (cont.): The University of Arizona College of Medicine Alumni Medal. This award for an outstanding alumni was presented at the University of Arizona College of Medicine in 1992. American Heart Association National Council for Basic Science, 1994-present. Experimental Biology 94 (Federation Meetings) - featured symposium speaker, 1994. Fellow, American College of Endocrinology, 1995. Who's Who in Science and Engineering, 1995 to present. Who's Who in American Education, 1996 to present. Featured speaker at Society of Nephrology, Republic of China, 1996. United States Patent No. 5,691,310. “Methods of Treatment Using ProANF Peptides”. Patent issued 11/25/1997. Who’s Who in America, 1998 to present. Who's Who in the World, 1998 to present. Who's Who in Medicine and Health Care, 1998-present. One Thousand Great Americans – The International Biographical Centre of Cambridge, England, 2001. Featured Plenary Speaker – On Atrial Natriuretic Peptides in the New Millennium at the European Renal Association Annual Meeting, June 24-27, 2001, Vienna, Austria. Lifetime Achievement Award – The International Biographical Centre of Cambridge, England, 2001. Experimental Biology 2002 - Featured Speaker and Chair of Symposium on “Diagnosis and Treatment with Atrial Natriuretic Peptides”, April 20-24, 2002, New Orleans, Louisiana. United States and International Patent 6,943,147. “Cancer treatment using proANP peptides”, issued 9/13/05. United States Patent Application 10/908,604 “Cancer treatment using C-natriuretic peptide”, issued 2/10/2009. United States Patent Application 11/074,063 “Oral methods of treatment using proANF peptides”, filed 3/8/2005. Foreign Filing License granted 5/24/2005.
  • 6. David L. Vesely, M.D., Ph.D. 6 Honors and Awards (cont.): United States and International Patent Application 11/162056 “Method of treatment of cancer using guanosine 3’,5’-cyclic monophosphate (cyclic GMP)”, filed 8/26/2005. America’s Top Physicians, Consumer Research Council of America, 2003, 2004, 2005, 2006, 2007, 2008, 2009. Featured Symposium Speaker and Chair of Symposium – “Diagnosis and Treatment Utilizing Natriuretic Peptides”. International Physiological Congress/Experimental Biology Meeting 2005. March 31-April 5, 2005, San Diego, California. (20,000+ scientists attending) United States Patent Application 60/746,562 “Urodilatin Cancer Treatment”, filed 5/5/2006. Tampa Bay Health Heroes, Lifetime Achievement Award finalist, sponsored by Tampa Bay Business Journal and Tampa Bay Business Community, 2006. United States Patent Application 11/833,757 “Dendroaspis natriuretic peptide”, filed August 3, 2007. American Medal of Honor – 2007 Presented by American Biographical Institute, Inc. Service to America Career Achievement Medal, 2007. Three finalists for this medal which included 2006 Nobel Prize winner were announced at a tribute breakfast in Caucus Room of Russell Senate Office Building in Washington DC on June 19, 2007. The Medal was presented to Dr. Vesely on September 19, 2007 at a gala black tie dinner celebration in Andrew Mellon Auditorium, Washington DC. Lester Holt, weekend anchor, NBC Nightly News & Today, was the Master of Ceremonies. The Selection Committee for the Medal were: Diana Aviv, President and CEO, Independent Sector Richard H. Brodhead, President, Duke University Jean Case, Chief Executive Office, Case Foundation Kenneth Chenault, Chairman and CEO, American Express Company Maureen F. Curley, President, Campus Compact Dan Glickman, Chairman and CEO, Motion Picture Association of America Stephen Goldsmith, Chair, Corporation for National and Community Service Lewis B. Kaden, Vice Chairman, Citigroup, Inc. Colleen M. Kelley, National President, National Treasury Employees Union U.S. Rep. Kenny Marchant, Texas Dina Habib Powell, Former Assistant Secretary, Educational and Cultural Affairs, U.S.
  • 7. David L. Vesely, M.D., Ph.D. 7 Department of State Kevin Reilly, President, University of Wisconsin System U.S. Rep. Christopher Shays, Connecticut Linda M. Springer, Director, Office of Personnel Management Max Stier, President and CEO, Partnership for Public Service U.S. Rep. Chris Van Hollen, Maryland U.S. Sen. John Warner, Virginia Joan Woodward, Executive Director, Global Markets Institute, Goldman, Sachs & Co. Fareed Zakaria, Editor, Newsweek International Featured Symposium Speaker and Chair of Symposium also featuring Adolfo deBold, PhD, University of Ottawa Heart Institute, John C. Burnett, Jr., M.D., Director of Cardio Renal Research Laboratories, Mayo Clinic and Walter Hörl, M.D., Director of Nephrology & Dialysis, University of Vienna (Austria) at Experimental Biology Meeting 2008, April 5-9th, 2008, San Diego, California (20,000+scientists attending). Title of Symposium: “Cardiac hormones: For the treatment of acute myocardial infarction, congestive heart failure, acute renal failure and cancer”, 2008. Distinguished Scientist Award. Presented at the 34th Annual International Clinical Ligands Society Meeting, Coral Springs, Florida, June 2-5, 2008. Keynote Speaker – The World Cancer Congress, Shanghai, China, June 12-17, 2008. Richard A. Kern Award – for the individual who has made outstanding contributions to federal medicine. Presented at the 114th Annual Meeting of the American Association of Military Surgeons of the United States, San Antonio, Texas, Nov. 9-14, 2008. 4,400 scientists and physicians attended Dr. Vesely’s award lecture. University, State and National Service: University: Endocrine, Diabetes, and Metabolism Clinics-weekly/twelve months/year (University and Veterans' Administration clinics) (1978 to present). Medicine Clinic Attending--twice per week throughout the year at University until 1985. From 1985 on, weekly at Veterans Administration Endocrine/Diabetic Clinics to present. Internal Medicine Ward Attending - 4 months/year (1978-2000). One month/year (2000- ). Physical Diagnosis: Since 1976, yearly has taught physical diagnosis. Internship Applicant Interviewer. Research Council for Research Development of the University of Arkansas for Medical
  • 8. David L. Vesely, M.D., Ph.D. 8 Sciences (1978-1981). Instructional Development and Education Awards Committee (1979-1989). Research Advisor to Dean's Institutional Self Study Analysis of the College of Medicine for the National Liaison Committee on Medical Education (1979-1989). Clinical Affairs Advisor to Dean of College of Medicine for Institutional Self Analysis for the National Liaison Committee on Medical Education (1985-1989). Product Evaluation and Standards Committee, University of Arkansas for Medical Sciences (1982-1989). Chairman, 1984. Council for Academic Affairs. University of Arkansas for Medical Sciences (1983-1989). Goals and Objectives of Medical Residency Committee. University of South Florida Medical School (1991- present). Dean's Committee for Evaluation of Department of Physiology, University of South Florida Health Sciences Center (1993-1994). Faculty Council, University of South Florida College of Medicine (1993-1997). Search for Chair, Department of Physiology, University of South Florida Health Sciences Center (1994-1995). Search Committee for two new faculty members in Department of Physiology, University of South Florida Health Sciences Center (1997). Search Committee for a new faculty member in Department of Physiology, University of South Florida Health Sciences Center (1998). University of South Florida Research and Creative Scholarship Program (1994 to present). Search for Director, Division of Cardiology, Department of Internal Medicine, University of South Florida Health Sciences Center (2000). Search for Director, Renal Division, Department of Internal Medicine, University of South Florida Health Sciences Center (2000). Review of Research and Grant Proposals, Department of Medicine, University of South Florida Medical School (2002-present). Medical School Representative for University of South Florida to Council of Southern Society for Clinical Investigation (2002-present). State and Federal:
  • 9. David L. Vesely, M.D., Ph.D. 9 Research and Development Committee, John L. McClellan Veterans Affairs Hospital, Little Rock, Arkansas (1987-1989). Research and Development Committee, James A. Haley Veterans Hospital, Tampa, Florida (1989-2001). Research Advisor to Arkansas Chapter of American Diabetes Association (1978-1989). Chairman, Professional Committee, Arkansas Chapter of American Diabetes Association. (1982-1985). Made a one-hour videotape "Diabetes and Its Complications," for Arkansas Public Television Network (1981). After being shown locally it was syndicated and has been shown on the National Public Television Network. Yearly lectures on "Diabetes Mellitus and Its Management" at Area Health Education Center in Fayetteville; at the Veterans' Administration Hospital in Fayetteville, and the Area Health Education Center in Pine Bluff. (1978-1989) Yearly lectures on various endocrine conditions at Little Rock Air Force Base Hospital. (1978-1989) Yearly lectures on endocrine diseases - Orlando Regional Medical Center, Orlando, Florida (1989-), Sarasota Regional Medical Center, Sarasota, Florida (1990-), Winter Park Memorial Hospital, Winter Park, Florida (1990-), Sun Bay - Humana Hospital, St. Petersburg, Florida (1990-present), and for Primary Care Physician, J. A. Haley Veterans Hospital (1990-present). Hillsborough County Public Schools and Tampa Catholic High School (Tampa, Florida) Teach In - Presentation to various grade schools and high schools of what a physician does and how new medical discoveries benefit people (1990-present). High School Science Teachers Summer Institute - 1991-Seminars on newest advances in medical science for teachers in the Hillsborough County School System. Drug Utilization and Evaluation Committee, James A. Haley Veterans Hospital (Tampa, Florida). This committee determines the utilization pattern and cost-effectiveness of drugs that are to be placed in the hospital pharmacy (1993-present). American Heart Association, Florida Affiliate, Research Peer Review Committee (1993-1997). Director's Risk Management Committee, James A. Haley Veterans Affairs Hospital (Tampa, Florida). Department of Medicine representative to committee that evaluates all potential lawsuits for Veterans Administration Hospital and advises the Director whether standard of care was met and whether potential lawsuit has any merit (1993-2005). Director of Diabetic and Endocrinology Clinics - John L. McCelllan Veterans Medical Center, Little Rock, Ark. - 1985-1989, James A. Haley Veterans Administration
  • 10. David L. Vesely, M.D., Ph.D. 10 Hospital, Tampa, Florida - 1993-present. Chairman of Diabetes Advisory Committee (to advise Director and Chief of Staff on all matters relating to diabetic patient care), James A. Haley Veterans Administration Hospital, Tampa, Florida, 1993- present. Made one-hour videotape “Prostate Cancer” for Florida Public Television Network (WEDU) in 1999. After being shown locally it was syndicated for National Public Television Network. First Annual African-American Men’s Health Forum, Tampa, Florida (2/26/2000). Featured speaker on “Diabetes Mellitus in African-American Men”. Second Annual African-American Men’s Health Forum, Tampa, Florida (2/24/01). Featured speaker on “Understanding Your Risk for Diabetes”. National: Reviewer for Am. Heart J., Am. J. Med, Sci., Am. J. Physiology, Archives of Internal Medicine, Biochim et Biophys Acta, Cardiovascular Research, Circulation, Endocrinology, Peptides, Metabolism, Journal of Clinical Endocrinology and Metabolism, and Science. Lectured on "Endocrine Emergencies" for the American College of Chest Physicians Critical Care Course in St. Louis, MO. Membership Committee. The Endocrine Society (1983-1986), Chairman (1985-1986). Department of Veterans Affairs Merit Review Study Section Grant Reviewer (1989- ). National Institutes of Health Study Section: Biochemical Endocrinology. Special Reviewer (1990- ). American Heart Association National Council for Basic Science (1994-present). American Heart Association - National: Review of investigator originated research grants (1996- ). Editorial Board - The American Journal of the Medical Sciences (2002-present). Academic Relations Task Force – Combined Committee of American Association of Clinical Endocrinologists and The Endocrine Society (2004-2007). National Institutes of Diabetes and Digestive Diseases Special Emphasis Panel (2007). Reviewer of NIH/NIDDK R01 Grant Applications. International Scientists Working in Dr. Vesely's Laboratory: Dr. Marie Rochat, Ph.D., Professor of Pharmacology, Laboratoire de Pharmacie. U.E.R. des Sciences Pharmaceutiques et Biologiques de Grenoble (France). Dr.
  • 11. David L. Vesely, M.D., Ph.D. 11 Rochat did her research for her Ph.D. (1980) in Dr. Vesely's laboratory. Quingfeng Kong, M.D., Post-Doctoral Fellow, Cardiology Research. Shanghai Medical School. People's Republic of China (1991-1992). Hanan Farghaly, M.D., Post-Doctoral Fellow. Alexandria University Medical School, Alexandria, Egypt (1998-1999). Imran Hassan, M.D., Post-Doctoral Fellow. Punjab Medical College, Faisalabad, Pakistan (1999-2000). Ehrentraud J. Eichelbaum, M.D., Post-Doctoral Fellow, University of Caracas, Venezuela (2006-2009). Ying Sun, M.D., Ph.D., Post-Doctoral Fellow, Dalian Medical University, Dalian, PR China (MD), National Key Laboratory of Nanobiological Technology, Ministry of Health, PR China (2006-2009). Anne Lenz, M.D., Pediatric Endocrine Fellow (2008-2010). American Board of Internal Medicine Certification: Board Certified in Internal Medicine Board Certified in Endocrinology, Diabetes, and Metabolism State Licensure: Diplomat, National Board of Medical Examiners, 1973 Florida State Medical License 1974 - present Arkansas State Medical License 1978 - present Grants: 1. National Institutes of Health Dental Research Scholarship--a scholarship covering all expenses leading to a Ph.D. degree (tuition, research, supplies, etc.) 1968-1972. The fellowship was utilized at the University of Arizona (Tucson, Arizona). 2. National Institutes of Health Post-Doctoral Fellowship (1974-1976). This scholarship paid salary and all research expenses for two years of endocrine research. 3. National Institutes of Health Biomedical Research Support Grant 5S07RR5350, Principal Investigator (1978-1980), $4,500. 4. Intergovernmental Personnel Act (IPA) Award from the National Center of Toxicological Research, Principal Investigator (1979-1981), $140,000. 5. National Institutes of Health Grant 1 FO6 TW00905-01. Senior Fogarty International Fellowship from John E. Fogarty International Center for Advanced
  • 12. David L. Vesely, M.D., Ph.D. 12 Study in the Health Sciences (1984-1985). This Grant was utilized to learn new research techniques at the Diabetes Branch of the National Institutes of Health of France. 6. Research Advisory Group Grant from the United States Veterans' Administration entitled "B complex vitamins. Receptor through protein phosphorylation", Principal Investigator (1986-1987), $10,000. 7. Dean's Committee Award for Outstanding Research. University of Arkansas for Medical Sciences for research entitled "Prohormone ANF factors: physiologic effects", Principal Investigator (1987-1988), $5,000. 8. University of Arkansas Institutional Grant entitled "Three potential antihypertensives: Prepro atrial natriuretic factors", Principal Investigator (1987-1988), $6,000. 9. Mr. and Mrs. Sam Walton Research Award from the University of Arkansas for Medical Sciences Foundation Fund for research entitled "Determination of whether prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 play a role in hypertension in the elderly", Principal Investigator (1988-1989), $7,200. 10. Merit Review Award from the Department of Veteran Affairs entitled "Pro atrial natriuretic factors: Circulating levels and physiologic effects", Principal Investigator (1989-1992), $200,600. 11. National Institutes of Health Grant HL44868 entitled "Cardiac peptides in the control of blood volume." Co-investigator (1991-1995), $333,440. 12. American Heart Association, Florida Affiliate Grant entitled "The role of ANF Prohormone in the Control of Blood Volume." Co-investigator (1991-1993), $80,000. 13. Merit Review Award from U.S. Department of Veterans Affairs entitled "Pro atrial natriuretic peptides: Physiologic and therapeutic effects." Principal Investigator (1993-1996), $200,000. 14. American Heart Association, Florida Affiliate Grant entitled "New cardiac peptides - Proatrial natriuretic peptides: Physiologic and therapeutic effects." Principal Investigator (1993-1996), $80,000. 15. American Heart Association, Florida Affiliate Grant entitled "The role of the heart in physiological control of the GI tract". Co-Investigator (1993-1995), $80,000. 16. Merit Review Award from U.S. Department of Veterans Affairs entitled "Pro atrial natriuretic peptides: Physiologic and therapeutic effects". Principal Investigator (1997-2000), $270,885. 17. American Heart Association, Grant-in-Aid entitled "Treatment of congestive heart failure with new atrial natriuretic peptides". Principal Investigator (1997-2000), $110,000.
  • 13. David L. Vesely, M.D., Ph.D. 13 18. National Institutes of Health Grant entitled “Secretion and renal effects of cardiac peptides”. Co-Investigator (1999-2003), $532,150. 19. American Heart Association Grant-in-Aid entitled “Treatment of congestive heart failure with new cardiac hormones”. Principal Investigator (2000-2002), $120,000. 20. Merit Review Grant from Department of Veterans Affairs entitled "Role of ANP and its receptors in stomach function and disease”. Co-Investigator (2000-2003), $353,800. 21. Darren Manelski Foundation (NY, NY) “Four cardiac hormones effects on the growth of human pancreatic adenocarcinomas in whole animals”. Principal Investigator (2003-2005), $48,000. 22. Merit Review Grant from United States Department of Veterans Affairs “Role of ANP and its receptors in stomach function and disease”. Co-Investigator (2004-2007), $495,000. 23. Merit Award from United States Department of Veterans’ Affairs entitled “Four cardiac hormones: Regulation of normal and abnormal growth”. Principal Investigator (2005-2009), $513,200. 24. Merit Review Grant from United States Department of Veterans Affairs “Adult stem cells in mouse models of neurodegeneration”. Co-Investigator (2008-2012), $500,000. 25. American Heart Association entitled “Regulation of VSMC Function by NPR-C: Role of AHNAK”. Co-Investigator (2010-2013), $500,000, pending. 26. Merit Review Grant from United States Department of Veterans Affairs entitled “Cardiac hormones: Regulation of normal and abnormal growth”. Principal Investigator (2010-2014), $633,900, pending. Professional Societies: American Association of Clinical Endocrinologists American College of Endocrinology, Fellow American College of Physicians, Fellow American Diabetes Association American Federation for Clinical Research American Medical Association The Endocrine Society International Endocrine Society International Society for Chronobiology New York Academy of Sciences
  • 14. David L. Vesely, M.D., Ph.D. 14 Society of Experimental Biology and Medicine Southern Society for Clinical Investigation Honor Societies: Sigma Xi. North American Research Honorary Teaching: Internal Medicine attending four months/year (1978-2000); one month/year 2000- present. Endocrinology attending five months for in-hospital consults, 12 months per year in endocrinology and metabolism clinics. Didactic Lectures on Internal Medicine for Junior Medical Students (a separate course from the teaching given on Internal Medicine attending rounds). Medicine Grand Rounds and Postgraduate courses, mainly teaching at American College of Physicians postgraduate courses. Clinical Correlation Course in Pathology for sophomore medical students (University of Arkansas for Medical Sciences). Physical Diagnosis - a ten-week course for sophomore medical students of five hours/day instruction on history and physical examinations (University of Miami and University of Arkansas for Medical Sciences). Endocrine Emergencies Course for Critical Care Nurses (University of Arkansas for Medical Sciences). Dietary management of Diabetes Mellitus for dieticians (University of Arkansas for Medical Sciences and University of South Florida For Health Sciences). Diabetes Insipidus and Inappropriate ADH Secretion for Anesthesiology Department. Medical Housestaff Orientation Lectures in Endocrinology and medical housestaff noon-time lecturer in Endocrinology (throughout the year at University of Arkansas for Medical Sciences, at Tampa General Hospital, and James A. Haley Memorial Veterans Medical Center, Tampa, Florida). Family Practice Grand Rounds on Thyroid Disease, Insulin Dependent Diabetes Mellitus, Cushing's Syndrome, Multiple Endocrine Neoplasia, and Prolactinomas (University of Arkansas for Medical Sciences). Lectures on Thyroid Cancer for Ears-Nose-Throat (ENT) Surgical Faculty and Housestaff (University of South Florida Health Sciences Center). Applied Pharmacology for Advanced Practice Health Care Professionals (James A. Haley Veterans Hospital, Tampa, Florida).
  • 15. David L. Vesely, M.D., Ph.D. 15 Diabetic Nurse Practitioner Program - Instruction and Supervision - weekly throughout year - (J.A. Haley Veterans Hospital, Tampa, Florida). Physiology Course for Freshman Medical Students: yearly lectures on Endocrine Physiology.
  • 16. David L. Vesely, M.D., Ph.D. 16 Publications: 1. Vesely, D.L., and Hadley, M.E.: Calcium requirements for melanophore- stimulating hormone action on melanophores. Science 173:923-925, 1971. 2. Vesely, D.L.: Ionic Requirements of Melanophore Regulation. University of Michigan Press, Ann Arbor, Michigan, pp. 1-89, (Ph.D. thesis), 1972. 3. Vesely, D.L., MacIntyre, D.S., and Ratzen, K.: Bilateral deep brachial vein thrombophlebitis due to Vibrio fetus. Arch. Intern. Med. 135:994-995, 1975. 4. Vesely, D.L., Chown, J., and Levey, G.S.: Guanylate cyclase activity in fetal, neonatal, and adult rat heart. J. Mol. Cell. Cardiology 8:909-913, 1976. 5. Vesely, D.L., Castro, A., and Levey, G.S.: The Somogyi effect in patient with hypopituitarism. Arch. Intern. Med. 136:936-938, 1976. 6. Vesely, D.L., and Hadley, M.E.: Receptor specific calcium requirement for melanophore stimulating hormone (MSH) control of melanophores. In Pigment Cell, Vol. 3, S. Karger, Basel, Switzerland, pp. 265-274, 1976. 7. Vesely, D.L., Rovere, L.E., and Levey, G.S.: Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosourea. Cancer Res. 37:28-31, 1977. 8. Vesely, D.L., and Levey, G.S.: Hydrazine activation of guanylate cyclase: Potential application to tobacco carcinogenesis. Biochem. Biophys. Res. Commun. 74:780-784, 1977. 9. Vesely, D.L. and Levey, G.S.: Enhancement of human guanylate cyclase activity by chemical carcinogens. Proc. Soc. Exp. Biol. and Med. 155:301-304, 1977. 10. Vesely, D.L., Maldonado, A., and Levey, G.S.: Partial hypopituitarism and possible hypothalamic involvement in sarcoidosis. Am. J. Med. 62:425-431, 1977. 11. Vesely, D.L., Graves, W.R., Lo, T.M., Fletcher, M.A., and Levey, G.S.: Isolation of a guanylate cyclase inhibitor from balsam pear (Momordica charantia abbreviata). Biochem. Biophys. Res. Commun. 77:1294-1299, 1977. 12. Vesely, D.L., and Levey, G.S.: Ethanol-induced inhibition of guanylate cyclase in liver, pancreas, stomach, and intestine. Res. Commun. Chem. Path. & Pharm. 17:215-224, 1977. 13. Vesely, D.L., Castro, A., and Levey, G.S.: Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus. Diabetes 26:308-313, 1977.
  • 17. David L. Vesely, M.D., Ph.D. 17 14. Lehotay, D.C., Levey, G.S., Vesely, D.L., Bornet, E.P., Ray, M.V., Entman, M.L., and Schwartz, A.: The effect of adenylate cyclase inhibitor (ACI) on guanylate cyclase, phosphodiesterase, and other enzymes in the heart. J. Cyclic. Nucleotide Res. 3:55-65, 1977. 15. Vesely, D.L., and Levey, G.S.: The effect of B-propiolactone, choloromethyl methyl ether, and ethionine on hepatic guanylate cyclase. IRCS Journal of Medical Sciences 5(8):365, 1977. 16. Vesely, D.L., and Levey, G.S.: Butadiene diepoxide activation of guanylate cyclase. Enzyme 23:140-143, 1978. 17. Vesely, D.L., and Levey, G.S.: The effect of streptozotocin analogues on guanylate cyclase activity. Horm. Metab. Res. 10(5):392-395, 1978. 18. Vesely, D.L., and Levey, G.S.: Nicotine decrease guanylate cyclase activity. Bull. Envir. Contam. & Toxicol. 20:31-34, 1978. 19. Vesely, D.L., and Levey, G.S.: Saccharin inhibits guanylate cyclase activity: Potential relationship to carcinogenesis. Biochem. Biophys. Res. Commun. 81(4):1384-1389, 1978. 20. Vesely, D.L., Lehotay, D.C., and Levey, G.S.: Modulation of rat guanylate cyclase activity in vitro by chemical carcinogens. Enzyme 23:356-360, 1978. 21. Vesely, D.L., Lehotay, D.C., and Levey, G.S.: Effect of ethanol on myocardial guanylate and adenylate cyclase activity and on cyclic GMP and AMP levels. J. Studies on Alcohol 39(5):842-847, 1978. 22. Vesely, D.L., and Mintz, D.H.: Acute renal failure in insulin dependent diabetics secondary to intravenous pyelography. Arch. Intern. Med. 138:1858-1859, 1978. 23. Vesely, D.L., Rovere, L.E., and Levey, G.S.: The effect of hydrazine, isonicotinic acid hydrazide, hydrazine sulfate, and dimethylhydrazine on guanylate cyclase activity. Enzyme 23:289-294, 1978. 24. Claflin, A.J., Vesely, D.L., Hudson, J.L., Bagwell, C.B., Lehotay, D.C., Lo, T.M., Fletcher, M.A., Block, N.L., and Levey, G.S.: Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proc. Natl. Acad. Sci. U.S.A. 75(2):989-993, 1978. 25. Vesely, D.L., Selawry, H., and Levey, G.S.: Correction of guanylate cyclase activity in diabetic rats by pancreatic islet cell transplantation. Transplantation 27:403-405, 1979. 26. Vesely, D.L.: Testosterone, its precursors and metabolites enhance guanylate cyclase activity in the rat. Proc. Natl. Acad. Sci. U.S.A. 76:3491-3494, 1979. 27. Vesely, D.L., and Hadley, M.E.: Ionic requirements for melanophore stimulating
  • 18. David L. Vesely, M.D., Ph.D. 18 hormone (MSH) action on melanophores. Comp. Biochem. Physiol. 62A:501-507, 1979. 28. Vesely, D.L., Watson, B. and Levey, G.S.: Activation of liver guanylate cyclase by paraquat: Possible role of superoxide anion. J. Pharmacol. & Exp. Therap. 209(1):162-164, 1979. 29. Vesely, D.L.: Phencyclidine stimulates guanylate cyclase activity. Biochem. Biophys. Res. Commun. 88(4):1244-1248, 1979. 30. Vesely, D.L.: Biochemical evidence of co-carcinogenesis: Tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity. Res. Commun. Chem. Path. Pharmacol. 24(12):329-338, 1979. 31. Vesely, D.L., and Levey, G.S.: Inhibition of nitroso chemical carcinogen activation of rat hepatic guanylate cyclase by anticancer agents. Oncology 36:122-126, 1979. 32. Carter, W.J., Vesely, D.L., Sanders, L.L., Faas, F.H., and Kohler, P.O.: Myxedema and the heart. J. Ark. Med. Soc. 76(4):169-175, 1979. 33. Vesely, D.L., Benson, W.R., Sheinin, E.B., and Levey, G.S.: Two components of laetrile (mandelonitrile and cyanide) stimulate guanylate cyclase activity. Proc. Soc. Exp. Biol. & Med. 161:319-321, 1979. 34. Vesely, D.L.: On the mechanism of action of adrenocortical steroids: Cortisol and aldosterone enhance guanylate cyclase activity. J. Pharmacol. Exp. Therap. 214:561-566, 1980. 35. Vesely, D.L., Bower, R.H., Kohler, P.O., and Char., F.: Familial ovarian dysgenesis in 46XX females. Am. J. Med. Sci. 80:157-166, 1980. 36. Vesely, D.L., and Cantell, K.: Human interferon enhances guanylate cyclase activity. Biochem. Biophys. Res. Commun. 96:574-579, 1980. 37. Vesely, D.L.: The interrelationship of somatostatin and guanylate cyclase activity. Mol. Cell. Biochem. 32:131-134, 1980. 38. Vesely, D.L., and Rochat, M.H.: Gibberellic acid, a plant growth hormone, enhances mammalian guanylate cyclase activity. Res. Commun. Chem. Path. Pharmacol. 28:123-132, 1980. 39. Vesely, D.L., and Hill, D.E.: Estrogens and progesterone increase fetal and maternal guanylate cyclase activity. Endocrinology 107:2104-2109, 1980.
  • 19. David L. Vesely, M.D., Ph.D. 19 40. Vesely, D.L.: The interrelationship of streptozotocin, its analogues and cyclic nucleotide metabolism. IN: Streptozotocin: Fundamentals and Therapy, M.K. Agarwal (ed), Elsevier/North Holland, Amsterdam, The Netherlands, pp 246-260, 1981. 41. Vesely, D.L.: Human and rat growth hormones enhance guanylate cyclase activity. Am. J. Physiol. 240:E79-E81, 1981. 42. Vesely, D.L., and Herbert, L.: Decreased tissue guanylate cyclase activity in glycosuric Djungarian hamsters (Phodopus sungorus) that is correctable with insulin. Horm. Metab. Res. 13:422-426, 1981. 43. Vesely, D.L.: Angiotensin II stimulates guanylate cyclase activity in aorta, heart and kidney. Am. J. Physiol. 240:E391-E393, 1981. 44. Vesely, D.L.: Melatonin enhances guanylate cyclase activity in a variety of tissues. Mol. Cell. Biochem. 35:55-58, 1981. 45. Vesely, D.L., and Faas, F.H.: Multiple endocrine adenomatosis with Cushing's disease and the amenorrhea-galactorrhea syndrome responsive to proton beam irradiation. South. Med. J. 74:1147-1149, 1981. 46. Vesely, D.L.: Bromocriptine enhances guanylate cyclase activity. Endocrinology 109:1284-1286, 1981. 47. Vesely, D.L., Straub, K.D., Nolan, C.M., Rolfe, R.D., Finegold, S.M., and Monson, T.P.: Purified Clostridium difficile cytotoxin stimulates guanylate cyclase activity and inhibits adenylate cyclase activity. Infec. Immun. 33:285-291, 1981. 48. Vesely, D.L.: Bee venon enhances guanylate cyclase activity. Science 213:359-360, 1981. 49. Vesely, D.L.: Hypoglycemic Coma: Don't overlook acute adrenal crisis. Geriatrics 37:71-77, 1982. 50. Rochat, M.H., Vesely, D.L., and Verain, A.: Activite metabolique des aromatisants. Labo Pharma Prob et Techniques 30:455-460, 1982. 51. Vesely, D.L.: Direct effect of glibeclamide on guanylate cyclase activity in the rat in vitro. Diabetologia 22:269-272, 1982. 52. Vesely, D.L.: Gila monster and Mexican beaded lizard venoms enhance guanylate cyclase activity. Res. Commun. Chem. Path. Pharm. 36:119-127, 1982. 53. Stuart, C.A., Vesely, D.L., Provow, S.A., and Furnaletto, R.W.: Cyclic nucleotides and somatomedin action in cartilage. Endocrinology 111:553-558, 1982.
  • 20. David L. Vesely, M.D., Ph.D. 20 54. Webster, K.M., Anderson, P.J., and Vesely, D.L.: The management of insulin- dependent diabetes in pregnancy. J. Ark. Med. Soc. 79:194-198, 1982. 55. Vesely, D.L.: Chapter 293, Weakness. In, Internal Medicine, Stein, J. (ed), Little Brown, Boston, pp 1694-1696, 1983. 56. Vesely, D.L., and Meiners, S.E.: Cimetidine partially blocks gastrin's activation of gastric mucosal guanylate cyclase. Endocrinology 112(6):1925-1929, 1983. 57. Vesely, D.L.: Biotin increases guanylate cyclase activity. Science 216:1329-1330, 1982. 58. Rochat, M.H., and Vesely, D.L.: Red dye no. 2 and the red pigment carmine enhance aryl hydrocarbon hydroxylase and guanylate cyclase activities. Biochem. Biophys. Res. Commun. 111(2):409-414, 1983. 59. Vesely, D.L.: Ergotamine and dihydroergatomine enhance guanylate cyclase activity. Res. Commun. Chem. Path. Pharm. 40:245-254, 1983. 60. Juan, D. and Vesely, D.L.: 1, 25-dihydroxyvitamin D3 is the most potent stimulator of human and rat renal cortical guanylate cyclase activity in vitro. In, Endocrine Control of Bone and Calcium Metabolism. Cohn, D.V., Fujita, T., Potts, J.T., Jr., and Talmage, R.V, eds. Elsevier, New York pp 372-375, 1984. 61. Vesely, D.L., Wormser, H.C., and Abramson, H.N.: Biotin analogs activate guanylate cyclase. Mol. Cell. Biochem. 60:109-114, 1984. 62. Vesely, D.L.: Cation-dependent prolactin activation of guanylate cyclase. Biochem. Biophys. Res. Commun. 123:1084-1090, 1984. 63. Canella, N.K., and Vesely, D.L.: The circadian rhythm of guanylate cyclase and its interrelationship to rat liver chalone. Res. Commun. Chem. Path. Pharm. 45(2):207-217, 1984. 64. Vesely, D.L., and Juan, D.: Cation dependent vitamin D activation of human renal cortical guanylate cyclase. Am. J. Physiology 246:E115-E120, 1984. 65. Mears, W.F., Boyd, C.M., and Vesely, D.L.: Superior vena cava syndrome secondary to thyroid enlargement reversed with thyroid hormone. South. Med. J. 78:1503-1506, 1985. 66. Vesely, D.L., Coleman, M.J., Kohler, P.O., Jordan, R.M., and Stanley, S.: Hyperalimentation as cause of markedly worsened metabolic control in a patient with autoantibodies to the insulin receptor. Am. J. Med. 79:504-508, 1985. 67. Scheving, L.A., Scheving, L.E., Tsai, T.H., and Vesely, D.L.: Epidermal growth factor enhances guanylate cyclase activity in vivo and in vitro. Endocrinology 116:332-336, 1985. 68. Vesely, D.L.: Cation-dependent gonadotropin releasing hormone activation of
  • 21. David L. Vesely, M.D., Ph.D. 21 guanylate cyclase. Mol. Cell. Biochem. 66:145-149, 1985. 69. Vesely, D.L., Hudson, J.L., Pipkin, J.L., Jr., Pack, L.D., and Meiners, S.E.: Plant growth promoting hormones activate mammalian guanylate cyclase activity. Endocrinology 116:1887-1892, 1985. 70. Turner, R.B., and Vesely, D.L.: Cerebral and cerebellar guanylate cyclase activities in patients with multiple sclerosis. Res. Commun. Chem. Path. Pharm. 49:313-316, 1985. 71. Vesely, D.L.: B complex vitamins activate rat guanylate cyclase and increase cyclic GMP levels. Eur. J. Clin. Investigation 15:258-262, 1985. 72. Vesely, D.L.: Cation-dependent substance P activation of the enzyme guanylate cyclase. Biochem. Biophys. Res. Commun. 128:141-147, 1985. 73. Heard, J.K., Bennett, W.G., Watson, R.A., and Vesely, D.L.: Acquired immunodeficiency syndrome in Arkansas. J. Ark. Med. Soc. 83:164-170, 1986. 74. Vesely, D.L.: The comparative effects of tolbutamide and the non-hypoglycemic analog carboxytolbutamide on guanylate cyclase activity. Horm. Metab. Res. 18:10-13, 1986. 75. Mangum, D.H., Bussell, K.L., Murphy, F.Y., Nicks, S.A., and Vesely, D.L.: Follicular thyroid carcinoma with pulmonary metastasis. J. Ark. Med. Soc. 83:271-279, 1986. 76. Vesely, D.L., Angtuaco, E., and Boyd, C.M.: Sinus tract in the neck: A rare complication of subtotal thyroidectomy for Graves' disease. Journal of Med. 17:253-261, 1986. 77. Vesely, D.L., Schedewie H., Kemp, S.F., Frindik, J.P., and Elders, M.J.: The post receptor defect in leprechaunism: decreased cyclic GMP and decreased guanylate cyclase activity. Pediatric. Res. 20:329-331, 1986. 78. Vesely, D.L., Mazurek, G.H., and Boyd, C.M.: Diabetic gastroparesis, immense weight loss, and diarrhea without steatorrhea. Am. J. Med. Sci. 293:255-260, 1987. 79. Vesely, D.L., and Bone, R.C.: Hyperalimentation-induced hyperosmolar nonketotic coma. J. Critical Illness 2:38-48, 1987. 80. Vesely, D.L., Bayliss, J.M., and Sallman, A.L.: Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. Biochem. Biophys. Res. Commun. 143:186-193, 1987. 81. Best, T.R., Jenkins, J.K., Murphy, F.Y., Nicks, S.A., Bussell, K.L., and Vesely, D.L.: Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am. J. Med. 82:676-680, 1987.
  • 22. David L. Vesely, M.D., Ph.D. 22 82. Vesely, D.L., and Sanders, L.L.: False elevation of hemoglobin A1c by hereditary persistence of fetal hemoglobin. J. of Med. 18:81-92, 1987. 83. Jenkins, J.K., Best, T.R., Nicks, S.A., Murphy, F.Y., Bussell, K.L., and Vesely, D.L.: Milk-alkali syndrome with a serum calcium of 22 mg/dl and J waves on the electrocardiogram. Southern Med. Journal 80:1444-1449, 1987. 84. Vesely, D.L., Norris, J.S., Walters, J.M., Jespersen, R.R., and Baeyens, D.A.: Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem. Biophys. Res. Commun. 148:1540-1548, 1987. 85. Vesely, D.L.: Weakness. Chapter 284. In, Internal Medicine. Stein, J. (ed). Little Brown, Boston. pp 1867-1869, 1987. 86. Murphy, F.Y., Vesely, D.L., Jordan, R.M., Flanigan S., and Kohler, P.O.: Giant invasive prolactinomas. Am. J. Medicine 83:995-1002, 1987. 87. Bussell, K.L., Murphy, F.Y., Nicks, S.A., and Vesely, D.L.: Facial flushing secondary to hypoglycemia. J. of Med. 18:123-132, 1987. 88. Vesely, D.L., Kemp, S.F., and Elders, M.J.: Isolation of a biotin receptor from hepatic plasma membranes. Biochem. Biophys. Res. Commun. 143:913-916, 1987. 89. Bennett, W.G., Watson, R.A., Heard, J.K., and Vesely, D.L.: Home hyperalimentation for common variable hypogammaglobulinemia with malabsorption secondary to intestinal nodular lymphoid hyperplasia. Am. J. Gastroenterology 82:1091-1095, 1987. 90. Vesely, D.L.: Mortality from hyperosmolar non-ketotic coma and diabetic ketoacidosis. J. Critical Illness 2(11):12-13, 1987. 91. Barton, G.M., Shoup, W.B., Bennett, W.G., Williams, J.B., and Vesely, D.L.: Combined Escherichia coli and Staphylococcus aureus thyroid abscess in an asymptomatic man. Am. J. Med. Sci. 31:133-136, 1988. 92. Winters, C.J., Sallman, A.L., Meadows, J., Rico, D.M., and Vesely, D.L.: Two new hormones: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate in man. Biochem. Biophys. Res. Commun. 150:231-236, 1988. 93. Vesely, D.L.: Selective pituitary resistance to thyroid hormone after treatment of a toxic multinodular goiter. Southern. Med. Journal. 81:1173-1176, 1988. 94. Winters, C.J., Sallman, A.L., and Vesely, D.L.: Circadian rhythm of prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 in man. Chronobiology Int. 5:403-409, 1988. 95. Vesely, D.L.: Recognition and managing of acute adrenal insufficiency. J. Critical Illness 3:101-111, 1988.
  • 23. David L. Vesely, M.D., Ph.D. 23 96. Baeyens, D.A., Walters, J.M., and Vesely, D.L.: Atrial natriuretic factor increases the magnitude of duodenal spontaneous phasic contractions. Biochem. Biophys. Res. Commun. 155:1437-1443, 1988. 97. Vesely, D.L., Winters, C.J., Sallman, A.L., Rico, D.M., Meadows, J., LeMay, B., Harris, J., Lunningham, S.D., and Melhorn, V.: Circadian variation of prohormone atrial natriuretic factors 1-30, 31-67, and 99-126 in man. Ann. Rev. of Chronopharmacology 5:469-472, 1988. 98. Vesely, D.L., Arnold, W.E., Winters, C.J., Sallman, A.L., and Rico, D.M.: Increased circulating concentration of atrial natriuretic factor in persons with pheochromocytomas. Clinical and Experimental Hypertension 11(3):353-369, 1989. 99. Vesely, D.L.: Hypothalamic sarcoidosis: A new etiology of morbid obesity. Southern Med. J. 82:758-761, 1989. 100. Vesely, D.L., Winters, C.J. and Sallman, A.L.: Prohormone atrial natriuretic peptides 1-30 and 31-67 increase in hyperthyroidism and decrease in hypothyroidism. Am. J. Med. Sci. 297:209-215, 1989. 101. Ngo, L., Wyeth, R.P., Bissett, J.K., Hester, W.L., Newton, M.T., Sallman, A.L., Winters, C.J. and Vesely, D.L.: Prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126 increase in proportion to right ventricular pacing rate. Am. Heart Journal. 117:385-390, 1989. 102. Vesely, D.L., Winters, C.J., and Sallman, A.L.: Atrial natriuretic factor in the pleural fluid of congestive heart failure patients. Chest 95:1107-1109, 1989. 103. Beland, S.S., Vesely, D.L., Arnold, W.C., Beavers, H.K., Gilbert, R., Henson, G.N., and Williamson, M.R.: Localization of adrenal and extra- adrenal pheochromocytomas by magnetic resonance imaging. Southern Med. J. 82: 1410-1413, 1989. 104. Winters, C.J., Sallman, A.L., Baker, B.J., Meadows, J., Rico, D.M., and Vesely, D.L.: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 80:438-449, 1989.
  • 24. David L. Vesely, M.D., Ph.D. 24 105. Vesely, D.L., Norsk, P., Winters, C.J., Rico, D.M., Sallman, A.L., and Epstein, M.: Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc. Soc. Exp. Biol. Med. 192:230-235, 1989. 106. Baeyens, D.A., Price, E., Winters, C.J., and Vesely, D.L.: Diving increases atrial natriuretic factor-like peptide in fresh water diving turtles. Comp. Physiol. Biochem. 94A:515-518, 1989. 107. Vesely, D.L., and Winters, C.J.: Atrial natriuretic factor in the ascitic fluid of cirrhotic patients. J. Medicine 20:208-216, 1989. 108. Winters, C.J., Baker, B.J., Dinh, H., Sallman, A.L., Rico, D.M., and Vesely, D.L.: Prohormone atrial natriuretic peptides 1-98 and 31-67 increase with exercise in congestive heart failure patients. Am. J. Med. Sci. 298:377-382, 1989. 109. McMurray, R.W. and Vesely, D.L.: Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Metabolism 38:1231-1237, 1989. 110. Bradford, D.S., Keppen, M., Sallman, A.L., Dinh, H., and Vesely, D.L.: Increased plasma concentration of atrial natriuretic factor with squamous cell carcinoma invasion of the right and left atria of the heart. Cancer 64:1909-1913, 1989. 111. Ngo, L., Vesely, D.L., Bissett, J.K., Murphy, M.L., Dinh, H., Seth, R., Sallman, A.L., Rico, D.M., Winters, C.J., Wyeth, R.P., Newton, M.T., and Hester, W.L.: Acute and sustained release of atrial natriuretic factor with acute myocardial infarction. Am. Heart J. 118:893-900, 1989. 112. Rico, D.M., Svendsen, F.J., Huffer, C., Smith, M., Pierce, R., Winters, C.J. and Vesely, D.L.: Increased release of atrial natriuretic factor with increasing atmospheres of pressure in a hyperbaric chamber and reversal with oxygen therapy. J. Medicine. 20:337-347, 1989. 113. Vesely, D. L., Kanabrocki, E. L., Sothern, R. B., Scheving, L. E., Tsai, T. H., Greco, J., Bushnell, D. L., Kaplan, E., Rumbyrt, J., Sturtevant, R., Sturtevant, F.M., Bremner, W.F., Third, J.L.H.C., Hrushesky, W.J.M., and Olwin, J. H.: The circadian rhythm of the N-terminus and C-terminus of the atrial natriuretic factor prohormone. Chronobiology Internat. 7:51-57, 1990. 114. Merkouris, R.W., Miller, F.C., Catanzarite, V., Rigg, L.A., Quirk, J.G., Jr., and Vesely, D.L.: Increase in the plasma levels of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor in normal pregnancy. Am. J. Obstet. Gynecol. 162:859-864, 1990. 115. Martin, D.R., Pevahouse, J.B., Trigg, D.J., Vesely, D.L., and Buerkert, J.E.: Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliuretic. Am. J. Physiology 258:F1401-F1408, 1990. 116. Vesely, D.L., Cornett, L.E., McCleod, S.L., Nash, A.A., and Norris, J.S.: Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126.
  • 25. David L. Vesely, M.D., Ph.D. 25 Peptides 11:193-197, 1990. 117. Vesely, D. L., Winters, C. J., and Sallman, A. L.: The N-terminus of the atrial natriuretic factor prohormone in the pleural fluid of congestive heart failure patients. Chest 97:1295-1298, 1990. 118. Ngo, L., Bissett, J.K., Winters, C.J., and Vesely, D.L.: Plasma prohormone atrial natriuretic peptides 1-98 and 31-67 increase with supraventricular and ventricular arrhythmias. Am. J. Med. Sci. 300:71-77, 1990. 119. Vesely, D.L.: Weakness, Chapter 327. In: Internal Medicine, 3rd edition. Stein, J. (ed.) Little Brown, Boston, pp. 2115-2117, 1990. 120. Vesely, D.L., Kanabrocki, E.L., Sothern, R.B., Scheving, L.E., Tsai, T.H., Greco, J., Bushnell, D.L., Kaplan, E., Rumbyrt, J., Sturtevant, R.P., Sturtevant, F.M., Bremner, W.F., Third, J.L.H.C., Hrushesky, W.J.M., and Olwin, J.H.: Circadian variation of new cardiac hormones that lower blood pressure and increase sodium excretion. Am. Rev. Chronopharmacology 7:137-140, 1990. 121. Vesely, D.L., and Winters, C.J.: Presence of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor in the ascitic fluid of cirrhotic patients. J. Medicine 21:265-275, 1990. 122. Rico, D.M., Svendsen, F.J., Huffer, C., Smith, M., Pierce, R., Winters, C.J., and Vesely, D.L.: Increased release of the N-terminus of the atrial natriuretic factor prohormone with increasing absolute atmospheres of pressure in a hyperbaric chamber. Chest 98:1403-1404, 1990. 123. Kanabrocki, E.L., Sothern, R.B., Scheving, L.E., Vesely, D.L., Tsai, T.H., Shelstad, J., Cournoyer, C., Greco, J., Mermall, H., Nemchausky, B.M., Bushnell, D.L., Kaplan, E., Kahn, S., Augustine, G., Holmes, E., Rumbyrt, J., Sturtevant, R.P., Sturetvant, F., Bremner, F., Third, J.L.H.C., McCormick, J.B., Mudd, C.A., Dawson, S., Olwin, J.H., Sackett-Lundeen, L., Haus, E., Halberg, F., Pauly, J.E., and Hrushesky, W.J.M.: Circadian reference data for men in fifth decade of life. Chronobiology: its role in clinical medicine, general biolgy, and agriculture. Part A, Wiley-Liss, Inc., pages 771-781, 1990. 124. Wyeth R.P., Ackerman, B.H., and Vesely, D.L.: The N-terminus, C-terminus, and Vessel Dilator of the ANF prohormone are present in the urine and increase with ventricular fibrillation. Biochem. Biophys. Res. Commun. 173:1030-1037, 1990. 125. Vesely, D.L., Arnold, W.C., Winters, C.J., Sallman, A.L., and Rico, D.M.: Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J. Clin. Endocrinol. Metab. 71:1138-1146, 1990. 126. Denker, P.S., Vesely, D.L., and Gomez-Sanchez, C.E.: Effect of pro atrial natriuretic peptides 1-30, 31-67, and 99-126 on angiotensin II-stimulated aldosterone production in calf adrenal cells. J. Steroid Biochem. 37:617-619, 1990.
  • 26. David L. Vesely, M.D., Ph.D. 26 127. Vesely, D.L. and Salmon, J.: Mechanical ventilation with positive end-expiratory pressure decreases the circulating concentrations of the N-terminus and C- terminus of the atrial natriuretic factor prohormone. Respiration 57:389-394, 1990. 128. Kanabrocki, E.L., Sothern, R.B., Scheving, L.E., Vesely, D.L., Tsai, T.H., Shelstad, J., Cournoyer, C., Greco, J., Mermall H., Ferlin, H., Nemchausky, B.M., Bushnell, D.L., Kaplan, E., Kahn, S., Augustine, G., Holmes, E., Rumbyrt, J., Sturtevant, R.P., Sturetvant, F., Bremner, F., Third, J.L.H.C., McCormick, J..B., Dawson, S., Sackett-Lundeen, L., Haus, E., Halberg, F., Pauly, J.E., and Olwin, J.H. : Reference values for circadian rhythms of 98 variables in clinically healthy men in the fifth decade of life. Chronobiol. Int. 7: 445-461, 1990. 129. Merkouris, R.W., Miller, F.C., Catanzarite, V., Quirk, J.G., Jr., Rigg, L.A., and Vesely, D.L.: The N-terminal and C-terminal portions of the atrial natriuretic factor prohormone increase during preeclampsia. Am. J. Obstet. Gynecol. 164:1197-1202, 1991. 130. Vesely, D.L., Baeyens, D.A., Winters, C.J., Elders, R. and Wewers, G.: Diving increases the N-terminus of the atrial natriuretic factor prohormone in freshwater diving turtles. Comp. Biochem. Physiol. 98A: 67-70, 1991. 131. Vesely, D.L., Elders, M.J., and Kemp, S.F.: Specific membrane receptors for proatrial natriuretic factors 1-30, 31-67, and 79-98 on isolated hepatic membranes. Life Science Adv. 10:15-20, 1991. 132. Ngo, L., Vesely, D.L., Bissett, J.K., Murphy, M.L., Dinh, H., Sallman, A.L., Rico, D.M., Winters, C.J., and Wyeth, R.P.: Acute and sustained release of the atrial natriuretic factor prohormone N-terminus with acute myocardial infarction. Am. J. Med. Sci. 301:157-164, 1991. 133. Winters, C.J., and Vesely, D.L.: Change in plasma immunoreactive N-terminus, C-terminus, and 4000 dalton mid portion of atrial natriuretic factor prohormone with hemodialysis. Nephron 58:17-22, 1991. 134. Vesely, D.L., Preston, R., Winters, C.J., Rico, D.M., Sallman, A.L., and Epstein, M.: Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in cirrhotic humans. Am. J. Nephrology 11:207-216, 1991. 135. Dietz, J.R., Nazian, S.J., and Vesely, D.L.: Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distention. Am. J. Physiol. 260:H1774-H1778, 1991. 136. Bradford, D.S., Keppen, M., Sallman, A.L., Dinh, H., and Vesely, D.L.: Increased plasma concentration of the N-terminus of the atrial natriuretic factor prohormone with squamous cell carcinoma invasion of the right and left atria of the heart. J. Exp. Clin. Cancer Res. 10:109-114, 1991.
  • 27. David L. Vesely, M.D., Ph.D. 27 137. Vesely, D.L. and Giordano, A.T.: Food intake and body positional change alter the circadian rhythm of atrial natriuretic peptides excretion into human urine. Chronobiol. Int. 8:373-384, 1991. 138. Godellas, C.V., Gower, W.R.Jr., Fabri, P.J., Knierim, T.H., Giordano, A.T., and Vesely, D.L. Atrial natriuretic factor (ANF) - A possible new gastrointestinal regulatory peptide. Surgery 110:1022-1027, 1991. 139. Kanabrocki, E.L., Sothern, R.B., Bremner, W.F., Gruber, S.A., Scheving, L.E., Bushnell, D.L., Ryan, M., Rubnitz, M.E., Fabbrini, N., Lampo, S., Cournover, C., Third, J.L.H.C., Mermall, H., Ferin, H., Vahed, S., Vesely, D.L., Sackett-Lundeen, L., Haus, E., and Olwin, J.H.: Heparin as a therapy for atherosclerosis: preliminary observations on the intrapulmonary administration of low-dose heparin in the morning vs evening gauged by its effect on blood variables. Chronobiol. Int. 8:210-233, 1991. 140. Vesely, D.L. and Giordano, A.T. Atrial natriuretic peptide hormonal system in plants. Biochem. Biophys. Res. Commun. 179:695-700, 1991. 141. Vesely, D.L.: Aprotinin blocks the binding of pro atrial natriuretic peptides 1-30, 31-67, and 99-126 to human placental membranes. Am. J. Obstet. Gynecol. 165:567-573, 1991. 142. Baker, B.J., Wu, W.L., Winters, C.J., Dinh, H., Wyeth, R., Sallman, A.L., and Vesely, D.L.: Exercise increases the circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in normal humans. Am. Heart J. 122:1395-1402, 1991. 143. Ackerman, B.H., Wyeth, R.P., Vesely, D.L., Ngo, L., Bissett, J.K., Winters, C.J., and Sallman, A.L.: Pharmacokinetic characterization of the postdistribution phase of prohormone atrial natriuretic peptides amino acids 1-98, 31-67, and atrial natriuretic factor during and after rapid right ventricular pacing in dogs. J. Clin. Pharmacol. 32:415-421, 1992. 144. Vesely, D.L., Palmer, P.A., and Giordano, A.T.: Atrial natriuretic factor prohormone peptides are present in a variety of tissues. Peptides 13:165-170, 1992. 145. McMurray, R.W., and Vesely, D.L.: Weight reduction decreases the circulating concentration of the N-terminus of the ANF prohormone. Am. J. Med. Sci. 303:2-8, 1992. 146. Vesely, D.L.: Peptides from the N-terminus of the atrial natriuretic factor prohormone enhance guanylate cyclase activity and increase cyclic GMP levels in a wide variety of tissues. Mol. Cell Biochem. 109:43-50, 1992. 147. Vesely, D.L. and Giordano, A.T.: The most primitive heart in the animal kingdom contains the atrial natriuretic peptide hormonal system. Comp. Biochem. Physiol. 101C:325-329, 1992.
  • 28. David L. Vesely, M.D., Ph.D. 28 148. Vesely, D.L. and Giordano, A.T.: Atrial natriuretic factor-like peptide and its prohormone within single cell organisms. Peptides 13:177-182, 1992. 149. Pevahouse, J.B., Flanigan, W.J., Winters, C.J., and Vesely, D.L.: Renal transplantation normalizes the elevated circulating N-terminal and C-terminal atrial natriuretic factor prohormone concentrations. Transplantation 53:1375-1377, 1992. 150. Dietz, J.R., Vesely, D.L., and Nazian, S.J.: The effect of changes in sodium intake on atrial natriuretic factor (ANF) and peptides derived from the N-terminus of the ANF prohormone in the rat. Proc. Soc. Exp. Biol. Med. 200:44-48, 1992. 151. Vesely, D.L., Sallman, A.L., and Bayliss, J.M.: Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol. Biochem. 15:23-32, 1992. 152. Vesely, D.L.: Inappropriate secretion of antidiuretic hormone. In, Principles and Practice of Emergency Medicine, 3rd Edition. Schwartz, G.R., Cayten, C.G., Mangelsen, M.A., Mayer, T. eds. Lea and Febiger, Philadelphia, Pa. pp. 2106-2111, 1992. 153. Ramirez, G., Saba, S.R., Dietz, J.R., and Vesely, D.L.: Immunocytochemical localization of proANF1-30, proANF 31-67, and atrial natriuretic factor (ANF) in the kidney. Kidney Int. 41:334-341, 1992. 154. Vesely, D.L., Gower, W.R, Jr., Giordano, A.T., and Friedl, F.E.: Atrial natriuretic peptides in the heart and hemolymph of the oyster, Crassostrea virginica: A comparison with vertebrates. Comp. Biochem. Physiol. 106B:535-546, 1993. 155. Vesely, D.L., Gower, W.R.Jr., and Giordano, A.T.: Atrial natriuretic peptides throughout the plant kingdom: Enhancement of solute flow by peptides from the N-terminus of the atrial natriuretic factor prohormone. Am. J. Physiol. 265:E465- E477, 1993. 156. McMurray, R.W.Jr., and Vesely, D.L.: Caloric restricted weight reduction, blood pressure and atrial natriuretic peptides. Nutrition 9:178-182, 1993. 157. Saba, S.R., Ramirez, G., and Vesely, D.L.: Immunocytochemical localization of proANF 1-30, proANF 31-67, atrial natriuretic factor (ANF) and urodilatin in the human kidney. Am. J. Nephrology 13:85-93, 1993.
  • 29. David L. Vesely, M.D., Ph.D. 29 158. Giordano, A.T., Raska-Emery, P., Montgomery, M.A., and Vesely, D.L.: Increased atrial natiuretic factor prohormone peptides in the heart but not in lung, liver, or intestine with aging. Growth, Development, and Aging. 57:111-120, 1993. 159. Vesely, D.L., Giordano, A.T., Raska-Emery, P. and Montgomery, M.R.: Ozone increases amino-and-carboxy terminal atrial natriuretic prohormone peptides in lung, heart and circulation. J. Biochem. Toxicology. 9:107-112, 1994. 160. Vesely, D.L., Douglass M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez-Paz, G. and Schocken, D.D.: Negative feedback of atrial natriuretic peptides. J. Clin. Endocrinol. Metab. 78:1128-1134, 1994. 161. Weston, M.W., Cintron G.B., Giordano, A.T., and Vesely, D.L: Normalization of circulating atrial natriuretic peptides in cardiac transplant recipients. Am. Heart J. 127:129-142, 1994. 162. Vesely, D.L., Giordano, A.T., Raska-Emery, P., and Montgomery, M.R.: Increases in atrial natriuretic factor in lungs, heart, and circulatory system owing to ozone. Chest 105:1551-1554, 1994. 163. Palmer, P.A., Friedl, F.E., Giordano, A.T. and Vesely, D.L.: Alteration of environmental salinity modulates atrial natriuretic peptides' concentrations in heart, and hemolymph of the oyster, Crassostrea virginica. Comp. Biochem. Physiol. 108A:589-597, 1994. 164. Poulos, J., Johnson, S.R., Conrad,P., Montero, J. and Vesely, D.L.: The dome lesion on chest x-ray: Retroperitoneal abscess dissecting through posterior chest wall. Southern Med. J. 87:77-80, 1994. 165. Vesely, D.L.: Atrial natriuretic peptides are stable in plasma for 7 years. Circulation 89: 2456-2457, 1994. 166. Gower, W.R. Jr., Chiou, S., Skolnick, K., and Vesely, D.L.: Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides 15:861-867, 1994. 167. Dietz, Jr., Vesely, D.L., and Nazian S.J.: Possible mechanism involved in the natriuretic response to atrial natriuretic factor (ANF) and pro ANF 31-67 in the rat. Clin. Exp. Pharmacol. & Physiology 21:599-606, 1994. 168. Vesely, D.L.: Weakness. Chapter 154. In: Internal Medicine, 4th edition. Stein, J. (ed.) Mosby-Year Book, Inc., St. Louis, pp 1266-1268, 1994. 169. Vesely, D.L., Douglass, M.A., Dietz, J.R., Gower, W.R. Jr., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90:1129-1140, 1994.
  • 30. David L. Vesely, M.D., Ph.D. 30 170. Vesely, D.L.: Atrial natriuretic peptides. Kidney: A Current Survey of World Literature 3:4-8, 1994. 171. Gower, W.R., Jr., Dietz, J.R., Vesely, D.L., Finley, C.L., Skolnick, K.A., Fabri, P.J., Cooper, D.E., and Chalfant, C.E.: Atrial natriuretic peptide gene expression in the rat gastrointestinal tract. Biochem. Biophys. Res. Commun. 202:562-570, 1994. 172. Vesely, D.L., Giordano, A.T., Raska-Emery, P., and Montgomery, M.R.: Ozone increase atrial natriuretic peptides in heart, lung, and circulation of aged versus adult animals. Gerontology 40:227-236, 1994. 173. Vesely, D.L.: Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohormone. Clin. Exp. Pharmacol. Physiology 22:108-114, 1995. 174. Sothern, R.B., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J.L.A.C., Boles, M.A., Nemachausky, B.M., Olwin, J.H., and Scheving, L.E.: Blood pressure and atrial natriuretic peptides correlate throughout the day. Am. Heart J. 129:907-916, 1995. 175. Ackerman, B.H., Wyeth, R.P., Soulsby M.E., Pappas A.A., and Vesely, D.L.: Vessel dilator is associated with survival after acute myocardial infarction. Int. J. Cardiology 47:235-244, 1995. 176. Vesely, D.L., Norsk, P., Gower, W.R., Jr., Chiou, S., and Epstein, M.: Release of kaliuretic peptide during immersion-induced central hypervolemia in healthy humans. Proc. Soc. Exp. Biol. Med. 209:20-26, 1995. 177. Palmer, P.A., Friedl, F.E., Giordano, A.T., and Vesely, D.L.: Alteration of environmental salinity modulates atrial natriuretic peptides concentrations in the gill of the oyster Crassostrea virginica. Comp. Biochem. Physiol. 110A:171-178, 1995. 178. Vesely, D.L., Chiou, S., Douglass, M.A., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. J. Endocrinology 146:373-380, 1995. 179. Habibullah, A.A., Villarreal, D., Freeman, R.H., Dietz, J.R., Vesely, D.L. and Simmons, J.C.: Infusion of atrial natriuretic factor prohormone peptides in dogs with experimental heart failure. Clin. Exp. Pharmacol. Physiology 22:130-135, 1995. 180. Chiou, S., and Vesely, D.L.: Kaliuretic peptide: The most potent inhibitor of Na+- K+-ATPase of the atrial natriuretic peptides. Endocrinology 136:2033-2039, 1995. 181. Poulos, J.E., Gower, W.R., Jr., Fontanet, H.L., Kalmus, G.W. and Vesely, D.L.: Cirrhosis with ascites: Increased atrial natriuretic peptide gene expression in rat
  • 31. David L. Vesely, M.D., Ph.D. 31 ventricle. Gastroenterology 108:1496-1503, 1995. 182. Dietz, J.R., Vesely, D.L., Gower, W.R., Jr., and Nazian, S.J.: Secretion and renal effects of ANF prohormone peptides. Clin. Exp. Pharmacol. Physiology 22:115-120, 1995. 183. Vesely, D.L., Giordano, A.T., Douglass, M.A, McCormick, M.T., Rodriguez-Paz, G. and Schocken, D.D.: Atrial natriuretic peptides and cyclic GMP metabolism. Am. J. Med. Sci. 310:143-149, 1995. 184. Sothern, R.B., Vesely, D.L., Kanabrocki, E.L., Hermida, R.C., Bremner, F.W., Third, J.L.A.C., Boles, M.A., Nemachausky, B.M., Olwin, J.H., and Scheving, L.E.: Temporal (Circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Chronobiol. Int. 12:106-120, 1995. 185. Phuphanich, S., Jacobs, I., Poulos, J.E. and Vesely, D.L.: Case report: Hypoglycemia secondary to a malignant meningioma. Am. J. Med. Sci. 309:317-321, 1995. 186. Chiou, S., and Vesely, D.L.: Dimethyl sulfoxide inhibits renal Na+-K+ ATPase at a site different from ouabain and atrial peptides. Life Sci. 57:945-955, 1995. 187. Cardona, O.L. and Vesely, D.L.: False-positive metastasis: A "floater" of thyroid tissue from another patient suggest malignancy. The Endocrinologist 5:431-434, 1995. 188. Poulos, J.E., Gower, W.R., Jr., Friedl, F.E., and Vesely, D.L.: Atrial natriuretic peptide gene expression within invertebratic hearts. Gen. and Comp. Endocrinology 100:61-68, 1995. 189. Vesely, D.L., Preston, R., Gower, W.R., Jr., Chiou, S., and Epstein, M.: Increased release of kaliuretic peptide during immersion-induced central hypervolemia in cirrhotic humans. Am. J. Nephrology 16:128-137, 1996. 190. Overton, R.M. and Vesely, D.L.: Processing of kaliuretic peptide in human plasma and serum. Peptides 17:1041-1046, 1996. 191. Vesely, D.L., Chiou, S., Douglass, M.A., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans. Metabolism 45:315-319, 1996. 192. Poulos, J.E., Gower, W.R., Jr., Sullebarger, J.T., Fontanet, H.L., and Vesely, D.L.: Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovascular Res. 32:909-919, 1996.
  • 32. David L. Vesely, M.D., Ph.D. 32 193. Vesely, D.L., Sothern, R.B., Scheving, L.E., Bremner, F.W., Third J.L.A.C., McCormick, J.B., Dawson, S., Kahn, S., Augustine, G., Ryan, M., Greco, J., Nemchausky, B.M., Shirazi, P., and Kanabrocki, E.L.: Circadian relationships between circulating atrial natriuretic peptides and serum calcium and phosphate in healthy humans. Metabolism 45:1021-1028, 1996. 194. Vesely, D.L., Blankenship, M., Douglass, M.A., McCormick, M.T., Rodriguez- Paz, G., and Schocken, D.D.: Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. Life Sci. 59:243-254, 1996. 195. Overton, R.M. and Vesely, D.L.: Processing of long acting natriuretic peptide and vessel dilator in human plasma and serum. Peptides 17:1155-1162, 1996. 196. Sothern, R.B., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third J.L.A.C., McCormick, J.B., Dawson, S., Ryan, M., Greco, J., Bean, J.T., Nemchausky, B.M., Shirazi P., and Scheving, L.E.: Circadian relationships between circulating atrial natriuretic peptides and serum sodium and chloride in healthy humans. Am. J. Nephrology 16:462-470, 1996. 197. Vesely, D.L.: Vessel dilator, long acting natriuretic peptide and kaliuretic peptide: New peptide hormones originating from the atrial natriuretic factor prohormone. In: Atrial Natriuretic Peptides, David L. Vesely, ed.: Research Signpost, Trivandum, India pp 87-110, 1997. 198. Dietz, J.R., Gower, W.R. Jr., Vesely, D.L., Nazian, S.J., Landon, C.S., and Skvorak, J.P.: Molecular species of atrial natriuretic peptide (ANP) prohormone secreted by isolated rat atria. In: Atrial Natriuretic Peptides. David L. Vesely, ed.: Research Signpost, Trivandum, India pp 119-127, 1997. 199. Daggubati, S., Parks, J.R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C- natriuretic prohormone peptides compared as early heart failure indicators. Cardiovascular Res. 36:246-255, 1997. 200. Ackerman, B.H., Overton, R.M., McCormick, M.T., Schocken, D.D., and Vesely, D.L.: Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. J. Pharmacol. Exp. Therap. 282:603-608, 1997. 201. Vesely, D.L.: Signal transduction: Activation of guanylate cyclase-cyclic guanosine-3’-5’ monophosphate system by hormones and free radicals. Am. J. Med. Sci. 314:311-323, 1997. 202. Cousins, K.L., Farrell, A.P., Sweeting, R.M., Vesely, D.L., and Keen, J.E.: Release of atrial natriuretic factor prohormone peptides 1-30, 31-67, and 99-126 from fresh-water and sea-water acclimated perfused trout (Oncorhynchus mykiss) hearts. J. Exp. Biol. 200:1351-1362, 1997. 203. Vesely, D.L., Overton, R.M., McCormick, M.T., and Schocken, D.D.: Atrial natriuretic peptides increase calcitonin gene-related peptide within human
  • 33. David L. Vesely, M.D., Ph.D. 33 circulation. Metabolism 46:818-825, 1997. 204. Wyeth, R.P., Soulsby, M.E., Vesely, D.L., and Kennedy, R.H.: Effects of lidocaine on atrial natriuretic peptide concentrations in plasma and urine. Life Sci. 60:473-477, 1997. 205. Vesely, D.L.: The family of atrial natriuretic peptides. Acta Nephrologica 11:119-135, 1997. 206. Vesely, D.L., Overton, R.M., Blankenship, M., McCormick, M.T., and Schocken, D.D.: Atrial natriuretic peptide increases urodilatin in the circulation. Am. J. Nephrology 18:204-213, 1998. 207. Vesely, D.L.: Weakness. Chapter 289. In: Internal Medicine, 5th Edition. Stein, J. (ed). Mosby, Inc., St. Louis, MO. pp 1753-1755, 1998. 208. Ramirez, G., Pineda, D., Bittle, P.A., Rabb, H., Rosen, R., Vesely, D.L., and Sasaki, S.: Partial resistance to arginine vasopressin as an adaptation to high altitude living. Aviat. Space Environ. Med. 69:58-65, 1998. 209. James, L.A., and Vesely, D.L.: Delayed onset angioedema after seven years of angiotensin converting enzyme inhibitor therapy. J. Pharm. Techol. 14:153-157, 1998. 210. Vesely, D.L.: Atrial natriuretic peptides within invertebrates and plants. Trends Comparative Biochem. & Physiol. 4:89-103, 1998. 211. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D.: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 98:323-329, 1998. 212. Vesely, D.L., Dietz, J.R., Parks, J.R., Antwi, E.K., Overton, R.M., McCormick, M.T., Cintron, G., and Schocken, D.D.: Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am. Heart J. 138:625-632, 1999. 213. Baig, M., Hintz, R.L., Baker, B.K., and Vesely, D.L.: Hypoglycemia attributable to insulin-like growth factor-II prohormone-producing metastatic leiomyosarcoma. Endocrine Practice 5:37-42, 1999. 214. Vesely, D.L., Gower, W.R. Jr., Dietz, J.R., Overton, R.M., Clark, L.C., Antwi, E.K., and Farese, R.V.: Elevated atrial natriuretic peptides and early renal failure in type II diabetic Goto-Kakizaki rats. Metabolism 48:771-778, 1999. 215. Yang, Q., Gower, W.R., Jr., Li, C., Chen, P., and Vesely, D.L.: Atrial natriuretic- like peptide and its prohormone within Metasequoia. Proc. Soc. Exp. Biol. Med. 221:188-192, 1999. 216. Vesely, D.L.: Inappropriate secretion of antidiuretic hormone. In, Principles and
  • 34. David L. Vesely, M.D., Ph.D. 34 Practice of Emergency Medicine, 4th Edition, Chapter 66. Schwartz, G.R., Hanke, B.K., Mayer, T.A., Conn, J.S., Dunn, J.D., Howton, J.C., Isaacman, D.J., Roth, P.R., Rothrock, S.G., Ungar, J.R. eds. Williams & Wilkins, Baltimore, MD, pp 969-972, 1999. 217. Beeson, M., Antwi, E.K., and Vesely, D.L.: Hydroxyurea-induced hypogonadism. The Endocrinologist 9:389-390, 1999. 218. Vesely, M.D., and Vesely, D.L.: Environmental upregulation of atrial natriuretic peptide gene in the living fossil, Limulus polyphemus. Biochem. Biophys. Res. Commun. 254:751-756, 1999. 219. Vesely, D.L., Dilley, R.W., Duckworth, W.C., and Paustian, F.F.: Hepatitis A- induced diabetes mellitus, acute renal failure, and liver failure. Am. J. Med. Sci. 317:419-424, 1999. 220. Vesely, D.L.: Atrial natriuretic peptides in the diagnosis and treatment of congestive heart failure. Congestive Heart Failure 5:171-179,183, 1999. 221. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. Life Sci. 66:905-913, 2000. 222. Gower, W.R. Jr., Salhab, K.F., Foulis, W.L., Pillai, N., Bundy, J.R., Vesely, D.L., Fabri, P.J., and Dietz, J.R.: Regulation of atrial natriuretic peptide gene expression in gastric antrum by fasting. Am. J. Physiology 278:R770-R780, 2000. 223. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion of β2 microglobulin. Metabolism 49:1592-1597, 2000. 224. Cole, B.A., Mendleblatt, D., Aguayo, J., Mathew, A., Martin, E., and Vesely, D.L.: Metastatic prostate cancer [with PSA of 9996] presenting as obstructive jaundice. Am. J. Med. Sci. 319:118-122, 2000. 225. Gower, W.R. Jr. and Vesely, D.L.: The gastrointestinal natriuretic peptide system. Trends Comp. Biochem. Physiol. 6:125-138, 2000. 226. Clark, L.C., Farghaly, H., Saba, S.R., and Vesely, D.L.: Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days. Am. J. Physiology 278:H1555-H1564, 2000. 227. Weston, M.W., Vijayangar, R., Overton, R.M., and Vesely, D.L.: Prospective evaluation of the Batista procedure with circulating atrial natriuretic peptides. Int. J. Cardiology 74:145-152, 2000. 228. Vesely, D.L., Mastrandrea, P., Samson, C., Argyelan, G., and Charvit, S.: Post- herpes encephalitic anterior pituitary insufficiency with hypothermia and hypotension. Am. J. Med. Sci. 320:273-277, 2000.
  • 35. David L. Vesely, M.D., Ph.D. 35 229. Vesely, D.L.: Congestive heart failure update: New cardiac peptides in diagnosis and treatment. Consultant 40:253-263, 2000. 230. Dizon, M.N., Henry, A.D., Beeson, M., and Vesely, D.L.: Generalized thyroid hormone resistance with possible selective cardiac non-resistance. Endocrine Practice 6:379-384, 2000. 231. Nasser, A., Dietz, J.R., Siddique, M., Patel, H., Khan, N., Antwi, E.K., Perez- Lamboy, G.I., McCormick, M.T., Schocken, D.D. and Vesely, D.L.: Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. Am. J. Cardiol. 88:23-29, 2001. 232. Vesely, D.L., San Miguel, G.I., Hassan, I., and Schocken, D.D.: Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin releasing hormone, corticotropin and cortisol. J. Clin. Endocrinol. Metab. 86:4244-4249, 2001. 233. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator and kaliuretic peptide enhance urinary excretion rate of β2 microglobulin in congestive heart failure patients. J. Cardiac Failure 7:55-63, 2001. 234. Lawrence, E., Lord, S.T., Leon, Y., McIntyre, P.J., Penix, J., Grebenev, D., and Vesely, D.L.: Tall cell papillary thyroid carcinoma metastatic to femur: Evidence for thyroid hormone synthesis within the femur. Am. J. Med. Sci. 322:103-108, 2001. 235. Vesely, M.D., Gower, W.R. Jr., Perez-Lamboy, G.I., Overton, R.M., Graddy, L., and Vesely, D.L.: Evidence for an atrial natriuretic peptide-like gene in plants. Exp. Biol. Med. 226:61-65, 2001. 236. Vesely, D.L.: Atrial natriuretic peptides in pathophysiological diseases. Cardiovascular Res. 51:647-658, 2001. 237. Vesely, D.L., San Miguel, G.I., Hassan, I., Gower, W.R. Jr., and Schocken, D.D.: Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and free T4 and free T3 with reciprocal increase in TSH. J. Clin. Endocrinol. Metab. 86:5438-5442, 2001. 238. Vesely, D.L.: Atrial natriuretic peptides: Modulation of other peptide and/or steroid hormones. Current Topics in Peptide & Protein Research 4:97-112, 2001. 239. Vesely, D.L., San Miguel, G.I., Hassan, I., and Schocken, D.D.: Intact negative feedback of four cardiac hormones in congestive heart failure. Metabolism 51: 582-588, 2002. 240. Jenq, W., Peguero, A., Cooper, D.R., and Vesely, D.L.: D-Glucose and NaCl
  • 36. David L. Vesely, M.D., Ph.D. 36 enhance the expression of aquaporin 1: Inhibition of both by cholera toxin. Nephron 92:279-286, 2002. 241. Dizon, M.N., and Vesely, D.L.: Gonadotrophin-secreting pituitary tumor associated with hypersecretion of testosterone and hypogonadism after removal of tumor. Endocrine Practice 8:225-231, 2002. 242. Vesely, D.L., San Miguel, G.I., Hassan, I., Gower, W.R. Jr., and Schocken, D.D.: Four cardiac hormones increase the circulating concentrations of luteinizing hormone and testosterone. Endocrine 17:145-150, 2002. 243. Gomez-Daspet, J., Elko, K., Grebenev, D., and Vesely, D.L.: Survival with serum sodium of 180 mEq/L: Permanent disorientation to place and time. Am. J. Med. Sci. 324:321-325, 2002. 244. Vesely, D.L., San Miguel, G.I., Hassan, I., and Schocken, D.D.: Atrial natriuretic hormone, long acting natriuretic hormone, vessel dilator and kaliuretic hormone decrease the circulating concentration of prolactin in healthy humans. Horm. Metab. Res. 34:245-249, 2002. 245. Vesely, D.L.: Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 53:153-159, 2002. 246. Kumar, M., Behera, A.K., Lockey, R.F., Vesely, D.L. and Mohapatra, S.S.: Atrial natriuretic peptide gene transfer by means of intra nasal administration attenuates airway reactivity in a mouse model of allergic sensitization. J. Allergy & Clinical Immunol. 110:879-882, 2002. 247. Gower, W.R., Jr., San Miguel, G.I., Carter, G.M., Hassan, I., Farese, R.V., and Vesely, D.L.: Atrial natriuretic prohormone gene expression in cardiac and extracardiac tissues of diabetic Goto-Kakizaki rats. Mol. Cell Biochem. 252:263-271, 2003. 248. Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L.: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur. J. Clin. Invest. 33:998-1005, 2003. 249. Vesely, D.L.: Natriuretic peptides and acute renal failure. (Review article) Am. J. Physiology 285:F167-F177, 2003. 250. Dietz, J.R., Vesely, D.L., Gower, W.R., Jr., Landon, C.S., Lee, S., and Nazian, S.J.: Neutralization of proANP 1-30 exacerbates hypertension in spontaneously hypertensive rat (SHR). Clin. Exp. Pharm. Physiol. 30:627-631, 2003. 251. Patel, H., Dietz, J.R., San Miguel, G.I., McCormick, M.T., Schocken, D.D., and Vesely, D.L.: Combined vessel dilator and kaliuretic hormone enhance the excretion rate of sodium, potassium, and water in persons with congestive heart failure but these effects are not additive. Exp. Biol. Med. 229:521-527, 2004. 252. Song, S., Kamath, S., Mosquera, D., Zigova, T., Sanberg, P., Vesely, D.L., and
  • 37. David L. Vesely, M.D., Ph.D. 37 Sanchez-Ramos, J.: Expression of brain natriuretic peptide by human bone marrow stromal cells. Experimental Neurology 185:191-197, 2004. 253. Gower, W.R., Jr., and Vesely, D. L.: Regulation of natriuretic peptides in the gastrointestinal tract. Current Topics Pharmacol., in press, 2004. 254. Dietz, J.R., Landon, C.S., Nazian, S.J., Vesely, D.L., and Gower, W.R., Jr.: Effects of cardiac hormones on arterial pressure and sodium excretion in NPRa knockout mice. Exp. Biol. Med. 229:813-818, 2004. 255. Sawmiller, D.R., Henning, R.J., Cuevas, J., Dehaven, W.I., and Vesely, D.L.: Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart. Neuropeptides 38:289-297, 2004. 256. Mohapatra, S.S., Lockey, R.F., Vesely, D.L. and Gower, W.R., Jr.: Natriuretic peptides and genesis of asthma: An emerging paradigm? J. Allergy & Clinical Immuol. 114:520-526, 2004. 257. Vesely, D.L. Clark, L.C., Garces, A.H., McAfee, Q.W., Soto, J., and Gower, W.R., Jr.: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur. J. Clin. Invest. 34:674-682, 2004. 258. Vesely, D.L.: Congestive Heart Failure Update: Cardiovascular hormones in diagnosis and treatment. Consultant 44:1390-1398, 2004. 259. Reiss, A.I., Socoloff, D.N., Owen, K., Greene, J., Vesely, D., and Cutolo, E.P.: Recurrent pneumonia after resection of colon carcinoma. Infect. Med. 21:531-539, 2004. 260. Vesely, B.A., Song, S., Sanchez-Ramos, J., Fitz, S.R., Solivan, S.M., Gower, W.R., Jr., and Vesely, D.L.: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur. J. Clin. Invest. 35:60-69, 2005. 261. Saba, S.R., Garces, A.H., Clark, L.C., Soto, J., Gower, W.R. Jr., and Vesely, D.L.: Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J. Histochem. Cytochem. 53:989-995, 2005. 262. Vesely, D.L.: Atrial natriuretic peptides: Anticancer agents. J. Invest. Med. 53:360-365, 2005. 263. Vesely, B.A., Song, S., Sanchez-Ramos, J., Fitz, S.R., Alli, A., Solivan, S.M., Gower, W.R., Jr., and Vesely, D.L.: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur. J. Clin. Invest. 35:388-398, 2005. 264. Vesely, B.A., Alli, A.A., Song, S., Gower, W.R., Jr., Sanchez-Ramos, J., and Vesely, D.L.: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur. J. Clin. Invest. 35:700-710, 2005. 265. Vesely, D.L.: Non-Insulin Dependent Diabetes Mellitius. In, Clinical Decisions in
  • 38. David L. Vesely, M.D., Ph.D. 38 Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 266. Vesely, D.L.: Insulin-Dependent Diabetes Mellitius. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 267. Vesely, D.L.: Insulin Allergy. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 268. Vesely, D.L.: Vasoactive Intestinal Polypeptide Producing Tumors. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Philadelphia, in press. 269. Vesely, D.L.: Endocrine Causes of Hair Growth. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 270. Vesely, D.L.: Diabetic Ketoacidosis. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 271. Vesely, D.L.: Glucagonomas. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 272. Vesely, D.L.: Somogyi Phenomenon - Nocturnal Hypoglycemia. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 273. Vesely, D.L.: Endocrine Causes of Muscle Weakness. In, Clinical Decisions in Endocrinology and Metabolism. Kohler, P.O. ed. B.C. Decker, Inc. Philadelphia, in press. 274. Gower, W.R., Jr., Vesely, B.A., Alli, A.A., and Vesely, D.L.: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3’,5’-cyclic monophosphate. Int. J. Gastrointestinal Cancer 36:77-87, 2005. 275. Vesely, D.L.: Which of the cardiac natriuretic peptides is the most effective for the treatment of congestive heart failure, renal failure, and cancer? Clin. Exp. Pharmacol. Physiol. 33:169-176, 2006. 276. Vesely, B.A., Fitz, S.R., Gower, W.R., Jr., and Vesely, D.L.: Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett. 232:226-231, 2006. 277. Kanabrocki, E.L., Vesely, D.L., Hermida, R.C., Ayala, D.E., Ryan, M.D., Burden, J., Shah, F., Friedman, N.C., Eladasari, B., Nemchausky, B.B., Dawson, S., McCormick, J.B., Alessandrini, S.M., and Hooper, D.C.: Circadian distribution of hematology variables in subjects with multiple sclerosis. Clin. Ter. 157:241-247, 2006.
  • 39. David L. Vesely, M.D., Ph.D. 39 278. Saba, S.R., and Vesely, D.L.: Cardiac natriuretic peptides: Hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers. Histology & Histopathology 21:775-783, 2006. 279. Vesely, B.A., Alli, A., Song, S., Sanchez-Ramos, J., Fitz, S.R., Gower, W.R., Jr., and Vesely, D.L.: Primary malignant tumors of the heart: Four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology 105:226-233, 2006. 280. Vesely, D.L.: Cardiac hormones: Dramatic anticancer effects. Cancer Therapy 4:253-262, 2006. 281. Eichelbaum, E.J., Vesely, B.A., Alli, A.A., Sun, Y., Gower, W.R., Jr., and Vesely, D.L.: Four cardiac hormones decrease up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine 30:325-332, 2006. 282. Sun, Y., Eichelbaum, E.J., Wang, H., and Vesely, D.L.: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res. 26:3217-3222, 2006. 283. Vesely, B.A., Eichelbaum, E.J., Alli, A.A., Sun Y., Gower, W.R., Jr., and Vesely, D.L.: Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur. J. Clin. Invest. 36:810-819, 2006. 284. Sun, Y., Eichelbaum, E.J., Wang, H., and Vesely, D.L.: Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res. 26:4143-4148, 2006. 285. Vesely, D.L., Eichelbaum, E.J., Sun, Y., Alli, A.A., Vesely, B.A., Luther, S.L., and Gower, W.R., Jr.: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21:445-452, 2007.
  • 40. David L. Vesely, M.D., Ph.D. 40 286. Vesely, D.L.: Discovery of new cardiovascular hormones for the treatment of congestive heart failure. Cardiovascular & Hematologic Disorders – Drug targets 7:47-62, 2007. 287. Vesely, D.L.: Natriuretic hormones. In Seldin and Giebisch’s, The Kidney: Physiology and Pathophysiology. 4th edition: Editors Robert J. Alpern and Steven C. Herbert. Elsevier Inc. pp. 947-977, 2007. 288. Vesely, B.A., Eichelbaum, E.J., Alli, A.A., Sun, Y., Gower, W.R., Jr., and Vesely, D.L.: Four cardiac hormones eliminate 4-fold more human glioblastoma cells than green mamba snake peptide. Cancer Lett. 254:94-101, 2007. 289. Vesely, B.A., Eichelbaum, E.J., Alli, A.A., Sun, Y., Gower, W.R., Jr., and Vesely, D.L.: Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am. J. Med. Sci. 334:342-349, 2007. 290. Vesely, D.L.: Infusion of cardiac natriuretic peptides to treat acute renal failure, congestive heart failure, and cancer. J. Infusion Nurs., in press, 2007. 291. Vesely, B.A., Eichelbaum, E.J., Alli, A.A., Sun, Y., Gower, W.R., Jr., and Vesely, D.L.: Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy 5:97-104, 2007. 292. Sun, Y., Eichelbaum, E.J., Wang, H., and Vesely, D.L.: Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J. Cancer Mol. 3 (4):113-120, 2007. 293. Vesely, D.L.: Urodilatin: A better natriuretic peptide? Curr. Heart Failure Rep. 4:147-152, 2007. 294. Sun, Y., Eichelbaum, E.J., Wang, H., and Vesely, D.L.: Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res. 27:1387-1392, 2007. 295. Vesely, D.L., Vesely, B.A., Eichelbaum, E.J., Sun, Y., Alli, A.A., and Gower, W.R., Jr.: Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 21:973-978, 2007. 296. Sun, Y., Eichelbaum, E.J., Wang, H., and Vesely, D.L.: Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res. 27:3813-3818, 2007. 297. Vesely, D.L.: New property of cardiac hormones: Anticancer effects in vitro and in vivo. In: Cardiac Hormones, D.L. Vesely, ed. Research Signpost, Trivandrum, India, pp 55-67, 2008. 298. Eichelbaum, E.J., Sun, Y., Alli, A.A., Gower, Jr., W.R., Vesely, D.L.: Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur. J. Clin. Invest. 38:562-570, 2008.
  • 41. David L. Vesely, M.D., Ph.D. 41 299. Vesely, D.L.: Cardiac Hormones: A 140-year history of experimentation leading to their identification. J Clinical Ligand Assay 31:8-14, 2008. 300. Vesely, D.L.: Cardiac Hormones: For the treatment and prognosis of renal failure. J. Clinical Ligand Assay 31:15-19, 2008. 301. Sun, Y., Eichelbaum, E.J., Wang, H., and Vesely, D.L.: Vessel dilator and kaliuretic peptide activate ERK 1/2 kinases in fibroblasts. Horm. Metab. Res. 41:197-201, 2009. 302. Sun, Y., Eichelbaum, E.J., Skelton, W.P. IV, Lenz, A., Regales, N., Wang, H., and Vesely, D.L.: Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res. 29:971-975, 2009. 303. Vesely, D.L.: Cardiac and renal hormones: Anticancer effects in vitro and in vivo. J. Invest. Med. 57:22-28, 2009. 304. Sun, Y., Eichelbaum, E.J., Lenz, A., Skelton, W.P. IV, Wang, H., and Vesely, D.L.: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res. 29:1889-1893, 2009. 305. Sun, Y., Eichelbaum, E.J., Lenz, A., Wang, H., and Vesely, D.L.: Four cardiac hormones inhibit insulin’s mitogenic action via inhibiting Ras. Cancer Therapy: 7:367-372, 2009. 306. Vesely, DL. Metabolic targets of cardiac hormones’ therapeutic anti-cancer effects. Current Pharmaceutical Design 16: In press, 2010. 307. Sun, Y., Eichelbaum, E.J., Lenz, A., Wang, H., and Vesely, D.L.: Epidermal growth factor’s activation of Ras is inhibited by four cardiac hormones. Eur. J. Clin. Invest. 40: In press, 2010. 308. Lenz, A., Sun, Y., Eichelbaum, E.J., Skelton, W.P., IV, Pi, G. and Vesely, D.L.: Twice weekly intravenous treatment of pancreatic cancer with atrial natriuretic peptide and vessel dilator. In Vivo: In press, 2010. 309. Lenz, A., Sun, Y., Eichelbaum, E.J., Skelton, W.P., IV, Pi, G. and Vesely, D.L.: Cardiovascular hormones eliminate some human squamous cell lung carcinomas in athymic mice. Eur. J. Clin. Invest. 40: In press, 2010. Books:
  • 42. David L. Vesely, M.D., Ph.D. 42 1. Vesely, D.L.: Atrial Natriuretic Hormones. Prentice Hall: Englewood Cliffs, N.J. 256 pgs, 1992. 2. Atrial Natriuretic Peptides. Editor: David L. Vesely, 31 authors. Research Signpost: Trivandum, India, 156 pgs, 1997. 3. Cardiac Hormones: Editor: David L. Vesely, 21 authors. Research Signpost: Trivandrum, India, 127 pgs, 2008.
  • 43. David L. Vesely, M.D., Ph.D. 43 Abstracts: 1. Vesely, D.L., and Hadley, M.E.: Calcium requirement for the melanophore- stimulating hormone action on melanophores. Calcified Tissue Abstracts: 4CT506, 1971. 2. Vesely, D.L., and Hadley, M.E.: Receptor specific calcium requirements for melanophore-stimulating hormone (MSH). Clin. Res. 20:221,1972. 3. Vesely, D.L.: Ionic requirements for melanophore regulation. Dissertation Abstracts International 33, No. 2, 1972. 4. Vesely, D.L., Castro, A., and Levey, G.S.: Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus. Proc. of the Fifty- eighth Annual Meeting of The Endocrine Society, p. 92, 1976. 5. Lerman, S., Vesely, D.L., Weinstein, R.S., Canterbury, J.M., and Levey, G.S.: Elevated serum parathyroid hormone concentrations in hyperthyroidism. Proc. of American Thyroid Association meetings, p. 6, 1976. 6. Vesely, D.L., Rovere, L., and Levey, G.S.: Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosourea. Clin. Res. 25(1):36A, 1977. 7. Vesely, D.L., Castro, A., and Levey, G.S.: Somoygi effect in patient with hypopituitarism. Excerpta Medica 37(6):267, 1977. 8. Vesely, D.L., Chown, J., and Levey, G.S.: Guanylate cyclase activity in fetal, neonatal, and adult rat heart. Excerpta Medica 40(2):436, 1977. 9. Vesely, D.L., Graves, W.R., Lo, T.M., Fletcher, M.A., and Levey, G.S.: Isolation of a specific guanylate cyclase inhibitor. Proc. of the Fifty-ninth Annual Meeting of The Endocrine Society, p. 99, 1977. 10. Vesely, D.L., Maldonado, A., and Levey, G.S.: Partial hypopituitarism and possible hypothalmic involvement in sarcoidosis. Am. J. Med. 672:A106, 1977. 11. Vesely, D.L., MacIntyre, D.S., and Ratzen, K.: Bilateral deep brachial vein thrombophlebitis due to Vibrio fetus. Excerpta Medica 35(6):376-377, 1977. 12. Vesely, D.L., and Levey, G.S.: Modulation of rat and human guanylate cyclase activity in vitro by chemical carcinogens. Clin. Res. 25(3):502A, 1977. 13. Vesely, D.L., and Levey, G.S.: Enhancement of human guanylate cyclase by chemical carcinogens. Excerpta Medica 39(16):319, 1978. 14. Vesely, D.L., and Levey, G.S.: Ethanol-induced inhibition of guanylate cyclase in liver, pancreas, stomach and intestine. Excerpta Medica 43(30):225,1978. 15. Vesely, D.L., Claflin, A.J., Hudson, J.L., Bagwell, C.B., Lehotay, D.C., Lo, T.M., Fletcher, M.A., and Levey, G.S.: Inhibition of growth and guanylate cyclase
  • 44. David L. Vesely, M.D., Ph.D. 44 activity of an undifferentiated prostrate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Clin. Res. 26(1):35A, 1978. 16. Vesely, D.L., Lehotay, D.C., and Levey, G.S.: Effects of ethanol on myocardial guanylate and adenylate cyclase activity and on cyclic GMP and AMP levels. Excerpta Medica 45(30):757, 1978. 17. Vesely, D.L., and Levey, G.S.: Inhibition of nitroso chemical carcinogen activation of rat liver guanylate cyclase activity by antitumor agents. Clin. Res. 26(3):537A, 1978. 18. Vesely, D.L.: Biochemical evidence of cocarcinogenesis: Tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity. Clin. Res. 26(6):777A, 1978. 19. Vesely, D.L., and Levey, G.S.: 2,3-Dihydro-38-oxobenzisosulfonazole (saccharin) inhibits guanylate cyclase activity: Possible relationship to carcinogenesis. Proc. of the 60th Annual Meeting of The Endocrine Society, p. 541, 1978. 20. Vesely, D.L., Watson, B., and Levey, G.S.: Activation of guanylate cyclase by paraquat: Possible role of superoxide anion. Clin. Res. 27(2):238A, 1979. 21. Monson, T.P. , Vesely, D.L., Nolan, C.M., and Straub, K.D.: Pseudomembranous colitis enterotoxin stimulates guanylate cyclase activity. Clin. Res. 27(2):455A, 1979. 22. Vesely, D.L., and Cantell, K.: Interferon enhances guanylate cyclase activity. Clin. Res. 27(2):359A, 1979. 23. Vesely, D.L.: The effect of testosterone, its precursors and metabolites on guanylate cyclase activity. Proc. of the Sixty-first Annual Meeting of The Endocrine Society, p. 206, 1979. 24. Vesely, D.L.: Growth hormone enhances guanylate cyclase activity. Proc. VI International Congress of Endocrinology, p. 333, 1980. 25. Vesely, D.L., and Rochat, M.H.: Gibberellic acid, a plant growth hormone, enhances mammalian guanylate cyclase activity. Clin. Res. 28(2):409A, 1980. 26. Vesely, D.L., and Mintz, D.H.: Acute renal failure in insulin-dependent diabetics: Episodes secondary to intravenous pyelography. Excerpta Medica 42(6):208, 1980. 27. Vesely, D.L.: On the mechanism of action of adrenocortical steroids: Cortisol and aldosterone enhance guanylate cyclase activity. Excerpta Medica 51(3):445, 1980. 28. Vesely, D.L., and Hadley, M.E.: Ionic requirements for melanophore-stimulating hormone (MSH) action on melanophores. Excerpta Medica 42(3):556, 1980.
  • 45. David L. Vesely, M.D., Ph.D. 45 29. Vesely, D.L.: Human and rat growth hormones enhance guanylate cyclase activity in the rat. Proc. of the Sixty-second Annual Meeting of The Endocrine Society, p. 242, 1980. 30. Vesely, D.L.: Angiotensinogen, Angiotensin I, Angiotensin II, and guanylate cyclase activity clarified by SQ 20, 881. Clin. Res. 28(5):884A, 1980. 31. Vesely, D.L., and Herberg, L.: Decreased guanylate cyclase activity in glycosuric Djungarian hamsters (Phodopus sungorus) that is correctable with insulin. Clin. Res. 28(5):834A, 1980. 32. Vesely, D.L.: Angiotensin II stimulates guanylate cyclase activity in aorta, heart, and kidney. Excerpta Medica 53(2):324, 1981. 33. Vesely, D.L.: Direct in vitro effect of glyburide on guanylate cyclase activity. Clin. Res. 29(2):425A, 1981. 34. Rochat, M.H., and Vesely, D.L.: Red dye no. 2 and the red pigment cochineal enhance aryl hydrocarbon hydroxylase, dimethylaniline oxidase, and guanylate cyclase. Clin. Res. 29(2):440A, 1981. 35. Stuart, C.A., Furnaletto, R.W., and Vesely, D.L.: Cyclic GMP as the second messenger for stomatomedin-C in cartilage. Clin. Res. 29(5):840A, 1981. 36. Vesely, D.L. Melatonin enhances guanylate cyclase activity in a variety of tissues. Excerpta Medica 46(3):257, 1982. 37. Vesely, D.L.: The interrelationship of somatostatin and guanylate cyclase activity. Excerpta Medica 54(3):134, 1982. 38. Vesely, D.L.: Biotin and d-Biotin-p-Nitrophenyl ester enhance guanylate cyclase activity. Clin. Res. 30(2):406A, 1982. 39. Vesely, D.L.: Bromocriptine enhances guanylate cyclase activity. Excerpta Medica 56(4):624, 1982. 40. Vesely, D.L.: Phenoxybenzamine blocks ergot alkaloid's enhancement of rat guanylate cyclase activity. Clin. Res. 30(2):412A, 1982. 41. Vesely, D.L.: Cimetidine partially blocks gastrin's enhancement of rat gastric mucosal guanylate cyclase activity. Proc. of the Sixty-fourth Annual Meeting of The Endocrine Society, p. 417, 1982. 42. Vesely, D.L., Sullivan, N.M., Straub, K.D., Monson, T.P., and Wilkins, T.D.: Clostridium difficile toxins A and B both enhance guanylate cyclase activity. Clin. Res. 31(2):378A, 1983. 43. Vesely, D.L., and Juan, D.J.: Cation dependent vitamin D activation of human renal cortical guanylate cyclase activity in vitro. Clin. Res. 31(2):399A, 1983.
  • 46. David L. Vesely, M.D., Ph.D. 46 44. Vesely, D.L.: Hypoglycemic coma: Don't overlook acute adrenal crisis. Geriatrics Digest 33:6, 1983. 45. Vesely, D.L.: All of the B complex vitamins activate the enzyme guanylate cyclase. Clin. Res. 32(2):327A, 1984. 46. Vesely, D.L., Hudson, J.L., Pipkin, J.L., Jr., and Pack, D.: Plant growth hormones activate mammalian guanylate cyclase activity. Proc. of the VII International Congress of Endocrinology, p. 1004, 1984. 47. Kemp, S., Elders, M.J., Schedewie, H.K., and Vesely, D.L.: Evidence for a post insulin receptor defect in leprechaunism: decreased cyclic GMP levels and guanylate cyclase activity. Clin. Res. 34(1):223A, 1986. 48. Sallman, A.L., Bayliss, J.M., and Vesely, D.L.: Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. Clin. Res. 35(1): 47A, 1987. 49. Walters, J.M., Jesperson, R.R., Vesely, D.L., and Baeyens, D.A.: The influence of atrial natriuretic factor on the force of peristaltic contractions and cyclic GMP levels in the small intestine. Ark. Acad. Sci., pg. 39, 1987. 50. Vesely, D.L., and Norris, J.S.: Prepro atrial natriuretic factors increase cyclic GMP in isolated smooth muscle cells and aorta. Clin. Res. 35(3):450A, 1987. 51. Sallman, A.L., Bayliss, J.M., and Vesely, D.L.: Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. Xth International Congress of Nephrology, pg. 219, 1987. 52. Peng, C.F., Murphy, M.L., Nash, A.A., and Vesely, D.L.: Atrial natriuretic factor increases the amplitude of contraction of cultured ventricular myocytes. J. Molecular Cellular Cardiology 19(Supp IV): 546, 1987. 53. Sallman, A.L., Winters, C.J., Meadows, J., and Vesely, D.L.: Human pro-atrial natriuretic factors (ANF) 1-30 and 31-67 circulate in normal human subjects. XX Meeting of American Society of Nephrology, p. 137 A, 1987. 54. Winters, C.J., Baker, B.J., Killingsworth, S., Cotter, B.L., Sallman, A.L., Meadows, J., Rico, D.M., and Vesely, D.L.: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate normally in man and increase in congestive heart failure. Proc. Soc. Exp. Biol. Med. 187(2):263, 1988. 55. Peng, C.F., Murphy, M.L., Nash, A.A. and Vesely, D.L.: Atrial natriuretic factor increases the amplitude of contraction of cultured ventricular myocytes. Circulation 76(Supp IV): p. 318, 1987. 56. Winters, C.J., Sallman, A.L., Meadows, J., Rico, D.M., and Vesely, D.L.: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate normally in man and increase in chronic renal failure. Clinical Research, 36(1):176A, 1988.
  • 47. David L. Vesely, M.D., Ph.D. 47 57. Vesely, D.L., Winters, C.J., Sallman, A.L., Rico, D.M., Meadows, J., LeMay, B., Harris, J., and Melhorn, V.: Circadian variation of prohormone atrial natriuretic factors 1-30, 31-67 and 99-126 in man. Proc. of III International Conference on Chronobiology: p. VIII-11, 1988. 58. Vesely, D.L., Winters, D.J., Sallman, A.L., Meadows, J., Killingsworth, A., Cotter, B.L., Rico, D.M., and Baker, B.J.: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate normally in man and increase in proportion to the severity of the abnormality of salt and water metabolism. Proceedings of 8th International Congress of Endocrinology, P. 585, 1988. 59. Winters, C.J., Baker, B.J., Killingsworth, S., Cotter, B.L., Sallman, A.L., Hester, W.L., Rico, D.M., and Vesely, D.L.: The effect of exercise on the plasma concentration of prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 in man. Clinical Res. 36(2):328, 1988. 60. Epstein, M., Loutzenhiser, R., Norsk, P., Winters, C.J., Rico, D.M., Hester, W.L., Sallman, A.L. and Vesely, D.L.: Responsiveness of prohormone atrial natriuretic peptides 1-30 and 31-67 during immersion-induced hypervolemia in normal humans. Am. J. Hypertension 1(3):128A, 1988. 61. Vesely, D.L., Winters, C.J., Sallman, A.L., Hester, W.L. and Rico, D.M.: Circulating prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126 increase in hyperthyroidism and decrease in hypothyroidism. Proceedings of the 70th meeting of the Endocrine Society. pg. 56, 1988. 62. Vesely, D.L., Arnold, W.C., Winters, C.J., Sallman, A.L. and Rico, D.M.: Increased circulating concentration of atrial natriuretic factor in persons with pheochromocytomas. Proceedings of Kyoto Symposium on Atrial Natriuretic Peptides, P. 55, 1988. 63. Ngo, L., Wyeth, R.P., Bissett, J.K., Hester, W.L., Newton, M.T., Rico, D.M., Sallman, A.L., Winters, C.J. and Vesely, D.L.: Release of prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126 increase in proportion to right ventricular pacing rate. J. Am. Coll. Cardiology 13:217A, 1989. 64. Ngo, L., Bissett, J.K., Murphy, M.L., Dinh, H., Seth, R.L., Newton, M.T., Hester, W.L., Sallman, S.L., Winters, C.J., and Vesely, D.L.: Increase of prohormone atrial natriuretic peptides 1-30, 31-67 and atrial natriuretic factor with acute myocardial infarction: Peak at day four. Clin. Res. 37:20A, 1989. 65. Ngo, L., Wyeth, R., Bissett, J.K., Hester, W.L., Newton, M.T., Rico, D.M., Sallman, A.L., Winters, C.J. and Vesely, D.L.: Release of prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 increase in proportion to right ventricular pacing rate. Clin. Res. 37:29A, 1989. 66. McMurray, R.W., Jr. and Vesely, D.L.: Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Proceedings of the 71st meeting of the Endocrine Society, pg. 305, 1989.
  • 48. David L. Vesely, M.D., Ph.D. 48 67. Pevahouse, J.B., Martin, D.R., Trigg, D.J., Winters, C.J., Vesely, D.L., and Buerkert, J.E.: Prohormone atrial natriuretic peptide 31-67 as well as atrial natriuretic factor causes a marked natriuresis. Clin. Res. 37(3):583A, 1989. 68. Rico, D.M., Svendsen, F.J., Huffer, C., Smith, M., Pierce, R., Winters, C.J., and Vesely, D.L.: Increased release of atrial natriuretic factor with increasing atmospheres of pressure in a hyperbaric chamber: Reversal with oxygen therapy. Clin. Res. 37(3):289A, 1989. 69. Ngo, L., Bissett, J.K., Murphy, M.L., Dinh, H., Seth, R., Wyeth, R., Sallman, A.L., Rico, D.M., Winters, C.J., and Vesely, D.L.: Acute and sustained release of N terminal and C-terminal portions of the prohormone of atrial natriuretic factor with acute myocardial infarction. Clin. Res. 37(3):282A, 1989. 70. Kanabrocki, E. L., Sothern, R. B., Scheving, L. E., Vesely, D. L., Tsai, T. H., Shelstad, J., Greco, J., Bushnell, D. L., Kaplan, E., Rumbyrt, J., Sturtevant, R., Sturtevant, F.M., Olwin, J. H., and Hrushesky, W.J.M.: Circadian reference data including prohormone atrial natriuretic peptides for men in fifth decade of life. Chronobiologica, 191, 1989. 71. Kanabrocki, E.L., Sothern, R.B., Olwin, J.H., Bremner, W.F., Bushnell, D.L., Ryan, M., Fabbrini, N., Lammpo, S., Cournover, C., Third, J.L.H.C., Mermall, H., Ferin, H., Vahed, A., Fareed, J., Vesely, D.L., Sackett-Lundeen, L., and Haus, E.: Intrapulmonary administration of heparin in the morning and its effect upon blood variables. Proc of IV International Conference on Chronobiology. VII-17, 1990. 72. Merkouris, R. W., Miller, F. C., Catanzarite, V., Rigg, L.A., Quirk, J.G., Jr., and Vesely, D. L.: Increase in the plasma levels of the N-terminal and C- terminal portions of the prohormone of atrial natriuretic factor in normal pregnancy. Clin. Res. 38(1):28A, 1990. 73. Vesely, D.L., Kanabrocki, E.L., Sothern, R.B., Scheving, L.E., Tsai, T.H., Greco, J., Bushnell, D.L., Kaplan, E., Rumbyrt, J., Sturtevant, R., Sturetvant, F.M., Bremner, W.F., Third, J.L.H.C., Hrushesky, W.J.M., and Olwin, J.H.: Circadian variation of new cardiac hormones that lower blood pressure and increase sodium excretion. Proc. of IV International Conference on Chronobiology. III-11, 1990. 74. Vesely, D.L., Arnold, W.C., Winters, C.J., Sallman, A.L., and Rico, D.M.: Increased circulating concentrations of the N-terminus and C-terminus of the atrial natriuretic factor prohormone in persons with pheochromocytomas. Proc. 72nd meeting of the Endocrine Society: 399, 1990. 75. Vesely, D.L., Winters, C.J., and Sallman, A.L.: The N-terminus and C-terminus of the atrial natriuretic factor prohormone in the pleural fluid of congestive heart failure patients. Clin. Res. 38(2):506A, 1990. 76. Godellas, C.V., Fabri, P.J., Gower, W.R., Jr., Knierim, T.H., Giordano, A.T., and Vesely, D.L.: Atrial natriuretic factor (ANF) - A new GI peptide hormone. Proc.
  • 49. David L. Vesely, M.D., Ph.D. 49 Am. Assoc. Endocrine Surgeons 12:38, 1991. 77. Baker, B.J., Wu, W.C., Winters, C.J., Dinh, H., Wyeth, R., Sallman, A.L. and Vesely, D.L.: Exercise increases the circulating concentration of the N-teminus of the atrial natriuretic factor prohormone in normal humans. Clin. Res. 39:226A, 1991. 78. Vesely, D.L. and Giordano, A.T.: Food intake and body positional change alter the circadian rhythm of atrial natriuretic peptides excretion into the urine. Clin. Res. 39:407A, 1991 79. Vesely, D.L., Giordano, A.T., and Friedl, F.E.: Atrial natriuretic peptides in invertebrates: Oyster ventricle, auricle, and blood contain all 126 amino acids of the atrial natriuretic factor prohormone. Clinc. Res. 39:365A, 1991. 80. McMurray, R.W., Jr., and Vesely, D.L.: Weight reduction decreases the circulating concentration of the N-terminus of the ANF prohormone and blood pressure in obese patients. Proc. 73rd Annual Meeting of the Endocrine Society: 204, 1991. 81. Saba, S.R., Ramirez, G., Dietz, J.R., and Vesely, D.L.: Immunocytochemical localization of proANF 1-30, proANF 31-67, and atrial natriuretic factor (ANF) in the kidney. Clin. Res. 39:848A, 1991. 82. Vesely, D.L., and Giordano, A.T.: The most primitive heart in the animal kingdom contains the atrial natriuretic hormonal system. Clin. Res. 39:872A, 1991. 83. Dietz, J.R., Vesely, D.L. and Nazian, S.J.: A comparison of the effects of atrial natriuretic factor (ANF) and proANF 31-67 on renal excretion and plasma renin activity. FASEB J.:A1491, 1992. 84. Vesely, D.L. and Giordano, A.T.: Atrial natriuretic peptide hormonal system is present throughout the plant kingdom and increases water flow up stems to flowers. Proc. IX International Congress of Endocrinology, page 151, 1992. 85. Saba, S.R., Ramirez, G., Dietz, J.R., and Vesely, D.L.: Immunocytochemical localization of proANF 1-30, proANF 31-67, and atrial natriuretic factor (ANF) in human and rat kidneys. Clin. Res. 40: 181A, 1992.
  • 50. David L. Vesely, M.D., Ph.D. 50 86. Wyeth R.P., Ackerman B.H., Soulsby, M.E., and Vesely, D.L.: Early effects of coronary artery occlusion on the plasma concentration kinectics of natriuretic prohormone N-terminus and C-terminus peptides. Proc. Soc. Exp. Biol. Mol. 200: 142, 1992. 87 Vesely, D.L.: Atrial natriuretic peptides: Chronobiological regulation. Proc. of the 5th International Conf. Chronopharmacol. Chronotherapeutics, pg 151, 1992. 88. Weston, M.W., Cintron, G.B., Giordano, A.T., and Vesely, D.L.: Normalization of atrial natriuretic peptides in cardiac transplant recipients. Cardiovascular Drugs and Therapy, 7:445, 1993. 89. Vesely, D.L., Douglas, M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez, G., and Schocken, D.D.: Two peptides from the atrial natriuretic factor prohormone amino terminus produce a significant natriuresis and diuresis in humans. Clin. Res. 41:117A, 1993. 90. Vesely, D.L., Gower W.R., Jr., Giordano, A.T., and Friedl, F.E.: Molecular species of atrial natriuretic peptides within vertebrate and invertebrate hearts. Clin. Res. 41:233A, 1993. 92. Palmar, P.A., Friedl, F.E., Giordano, A.T., and Vesely, D.L.: Alteration of environmental salinity modulates atrial natriuretic peptide concentrations in heart, gills and hemolymph of the oyster. Clin. Res. 41: 347A, 1993. 92. Vesely, D.L. Gower, W.R., Jr., and Giordano, A.T.: Molecular species of atrial natriuretic peptides within plants: Comparison with molecular species within animal hearts and circulation. Proc. of 75th Meeting of the Endocrine Society, 75:249, 1993. 93. Wyeth, R.P., Soulsby, M.E., and Vesely, D.L.: Plasma concentrations of atrial natriuretic prohormone N-terminus peptides during the first hour of acute percutaneous occlusion of the left anterior descending artery. Pro. Soc. Exp. Biol. Med. 203:259, 1993. 94. Vesely, D.L., Douglass, M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Prohormone atrial natriuretic peptide 79-98 (Kaliuretic Stimulator) lowers blood pressure and increases potassium excretion. Circulation 88:I-331, 1993. 95. Dietz, J.R., Nazian, S.J., and Vesely, D.L.: Comparison of intrarenal infusions of atrial natriuretic factor (ANF) and ANF prohormone peptides in the rat. J. Am. Soc. Nephrol. 4:437, 1993. 96. Vesely, D.L., Douglass, M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D. Negative feedback of atrial natriuretic peptides. Clin. Res. 41:800A, 1993. 97. Vesely, D.L.: Overview of atrial natriuretic factor prohormone peptides. FASEB 8:279, 1994.
  • 51. David L. Vesely, M.D., Ph.D. 51 98. Dietz, J.R., Vesely, D.L., Gower, W.R., Jr., and Nazian, S.J.: Secretion and renal effects of ANF prohormone peptides. FASEB 8:279, 1994. 99. Habibullah, A.A., Villarreal, D., Freeman, R.H., Dietz, J.R., Vesely, D.L., and Simmons, J.C.: Infusion of atrial natriuretic factor prohormone peptides in dogs with experimental heart failure. FASEB 8:279, 1994. 100. Gower, W.R., Jr., Finley, C., Dietz, J.R., Vesely, D.L., Fabri, P.J., and C. Chalfont.: Expression and regulation of atrial natriuretic peptide mRNA in rat gastrointestinal tract. Gastroenterology 106:A810, 1994. 101. Stanek E.J., Spinler, S.A., Cheng, J.W.M., Charland, S.L., Kobrin, S., and Vesely, D.L.: Reduction in circulating atrial natriuretic peptides following intravenous digoxin administration. Pharmocotherapy 14(3):348, 1994. 102. Gower, W.R., Jr., Choiu, S., Skolnick, K.A., and Vesely, D.L.: Molecular species of circulating atrial natriuretic peptides and their metabolites. Clin. Res. 42:343A, 1994. 103. Friedl, F.E., and Vesely, D.L.: Atrial natriuretic peptides in hemolymph and tissues of the eastern oyster, Crassostrea virginica. Proc. Natl. Shellfisheries Assoc. 53:9, 1994. 104. Vesely, D.L., Sothern, R.B., Kanabrocki, E.L., Bremner, F.W., Third, J.L.A.C., Boles, M.A., Nemchausky, B.M., Olwin, J.A., and Scheving, L.E.: Temporal (circadian) and functional relationships between atrial natriuretic peptides and blood pressure. Proc. of VI International Conference on Chronopharmacology and Chronotherapeutics, III-B-5, 1994. 105. Poulos, J., Gower, W.R., Jr., Fontanet, H., and Vesely, D.L.: Cirrhosis with ascites: Increased atrial natriuretic peptide messenger RNA synthesis in rat ventricle. Am. J. Gastroenterology 89:1176, 1994. 106. Poulos, J.E., Phuphanich, S., and Vesely, D.L.: Hypoglycemia secondary to a malignant meningioma. Am. College of Physicians 66:15, 1995. 107. Poulos, J., Vesely, D.L., Gower, W.R., Jr., and Fontanent, H.: Increased rat atrial natriuretic peptide mRNA synthesis in cirrhosis and congestive heart failure. Am. College of Physicians 66:20, 1995. 108. Villarreal, D., Habibullah, A.A., Freeman, R.H., Dietz, J.R., Vesely, D.L., and Knoblich, P.: Temporal changes in pro atrial natriuretic factor 31-67 in experimental heart failure. F.A.S.E.B. Journal 9:A78, 1995.
  • 52. David L. Vesely, M.D., Ph.D. 52 109. Habibullah, A.A., Villarreal, D., Freeman, R.H., Dietz, J.R., Vesely, D.L., and Knoblich, P.: Effects of cyclooxygenase inhibition on the renal actions of atrial natriuretic prohormone fragment 31-67 in normal dogs. F.A.S.E.B. Journal 9:A296, 1995. 110. Chiou, S. and Vesely, D.L.: Kaliuretic peptide: The most potent inhibitor of Na+- K+ATPase of the atrial natriuretic peptides. J. Investigative Med. 43:320A, 1995. 111. Poulos, J.E., Gower, W.R., Jr., Friedl, F.E., and Vesely, D.L.: Atrial natriuretic peptide gene expression within invertebrate hearts. J. Investigative Med. 43:268A, 1995. 112. Vesely, D.L., Chiou, S., Douglass, M.A., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. J. Investigative Med. 43:240A, 1995. 113. Vesely, D.L., Norsk, P., Gower, W.R., Jr., Chiou, S. and Epstein, M.: Release of kaliuretic peptide during immersion-induced central hypervolemia in healthy humans. J. Investigative Med. 43:260A, 1995. 114. Gower, W.R., Jr., Finley, C.L., Dietz, J.R., Vesely, D.L., and Fabri, P.J.: Regulation and localization of atrial natriuretic peptide mRNA in rat stomach. Gastroenterology 108:A971, 1995. 115. Habibullah, A.A., Villarreal, D., Freeman, R.H., Knoblich, P.R., Dietz, J.R. and Vesely, D.L.: Effects of indomethacin on the renal actions of atrial natriuretic prohormone fragment 31-67 in normal dogs. J. Investigative Med. 43:452A, 1995. 116. Gower, W.R. Jr., Sexton, C., Dietz, J.R., Vesely, D.L., and Fabri, P.J.: Expression and regulation of natriuretic peptide receptor A and B mRNAs in rat stomach. Gastroenterology 110:1074A, 1996. 117. Vesely, D.L., Blankenship, M., Douglass, M.A., McCormick, M.T., Rodriguez- Paz, G., and Schocken, D.D.: Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. Proc. X International Congress of Endocrinology 10:76, 1996. 118. Sothern, R.B., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J.L.H.C., McCormick, J.B., Dawson, S., Ryan, M., Greco, J., Bean, J.T., Nemchausky, B.M., Shirazi, P., and Scheving, L.E.: Circadian relationships between circulating atrial natriuretic peptides and serum sodium and chloride in healthy humans. Proc. X International Congress of Endocrinology 10:318, 1996. 119. Marshall, R.M. and Vesely, D.L.: Molecular processing kaliuretic peptide in human plasma and serum. Proc. X International Congress of Endocrinology 10:323, 1996. 120. Yandle, T.G., Vesely, D.L., Hunt, P.J., Espiner, E.A., Richards, A.M., Nicholls,
  • 53. David L. Vesely, M.D., Ph.D. 53 M.G., and Sage, M.: Intracardiac forms of BNP in humans: Evidence for amino terminal BNP formation from pro BNP prior to secretion. Proc. X International Congress of Endocrinology 10:324, 1996. 121. Cousins, K.L., Farrell, A.P., Sweeting, R.W., Vesely, D.L. and Keen, J.E.: Release of atrial natriuretic factor prohormone peptides 1-30, 31-67, and 99-126 from perfused hearts of freshwater and seawater acclimated trout. Proceedings of the Society of Experimental Biology 50:A12, 1997. 122. Daggubati, S., Parks, J.R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Comparison of atrial natriuretic peptide, brain natriuretic peptide, C- natriuretic peptide, adrenomedullin, N-terminal proatrial and probrain natriuretic peptides as indicators of early congestive heart failure. J. Investigative Med. 45:211A, 1997. 123. Daggubati, S., Parks, J. R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Vessel Dilator (i.e., proANF 31-67) is the best plasma indicator of mild congestive heart failure (CHF): Comparison with seven other putative peptide markers of CHF. Proc. of the Seventy-ninth Annual Meeting of the Endocrine Society 79:106, 1997. 124. Daggubati, S., Parks, J. R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Comparison of atrial, brain, C-, proatrial and probrain natriuretic peptides, adrenomedullin, endothelin, and neuropeptide Y as indicators of early congestive heart failure. Eur. Heart J. 18 Abst. Suppl.: 293, 1997. 125. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D.: Vessel dilator stimulates sodium and water diuresis in humans with congestive heart failure. Proc. of Heart Failure Society of America 1:10, 1997. 126. Bundy, J.R., Shafii, A.E., Salhab, K.S., Vesely, D.L., Fabri, P.J., Matsui, H., and Gower, W.R., Jr.: Expression of functional natriuretic peptide receptors in rat gastric mucosal (RGM1) cells. Gastroenterology 114:A1132, 1998. 127. Calderon, E., Anderson, W. McD., Rolfe, M.W., Rumbak, M.J., Overton, R.M., Liu, Z. and Vesely, D.L.: Dexamethasone increases production of vessel dilator in pulmonary epithelial cells. Am. J. Respiratory and Critical Care Med. 157:A198, 1998. 128. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D.: Treatment of congestive heart failure with a new natriuretic peptide. Proc. of XIII World Congress of Cardiology 13:35, 1998. 129. Stambler, B., Vesely, D.L., Ellenbogen, K., Griffin, J., Wilkoff, B., Keim, S. and Lamas, G.: A prospective comparison of atrial natriuretic factor (ANF) plasma levels in patients randomized to permanent VVIR compared with DDDR pacing mode in the PASE trial. PACE 21:915, 1998.
  • 54. David L. Vesely, M.D., Ph.D. 54 130. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D.: A new cardiac hormone enhances sodium and water diuresis in humans with congestive heart failure. Proc. of 80th Annual Meeting of the Endocrine Society 80:331, 1998. 131. Bundy, J.R., Yolain, J., Fabri, P.J., Vesely, D.L., and Gower, W.R., Jr.: Localization of ANP receptor subtypes in rat antrum. Gastroenterology 116:A594, 1999. 132. Vesely, D.L., Gower, W.R., Jr., Dietz, J.R., Overton, R.M., Clark, L.C., Antwi, E.K., and Farese, R.V.: Elevated atrial natriuretic peptides and early renal failure in type II diabetic Goto-Kakizaki rats. Proc. of 81st Annual Meeting of the Endocrine Society 81:220, 1999. 133. Hermida, R.C., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J., Ryan, M., Johnson, M., Shirazi, P., Nemchausky, B.A., and Scheving, L.E.: Circadian variation in serum atrial natriuretic prohormones and blood pressure in aging male subjects. Am. J. Hyperts. 13:307A-308A, 2000. 134. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of β2 microglobulin. Proc. of 82nd Annual Meeting of the Endocrine Society 82:308, 2000. 135. Dizon, M.N., Henry, A.D., Beeson, M., and Vesely, D.L.: Generalized thyroid hormone resistance with possible selective cardiac non-resistance. Proc. of 82nd Annual Meeting of the Endocrine Society 82:597, 2000. 136. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of β2 microglobulin in congestive heart failure. J. Cardiac Failure 6:98, 2000. 137. Hermida, R.C., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J., Ryan, M., Johnson, M., Shirazi, P., Nemchausky, B.A., and Scheving, L.E.: Circadian pattern in serum atrial natriuretic prohormones in relation to blood pressure in aging male subjects. J. Hypertens. 18 (Suppl. 2):S121, 2000. 138. Jeng, W., Cooper, D.R., Vesely, D.L., and Peguero, A.: Aquaporin-1 and Na+, K+ ATPase α expression in human proximal tubule epithelial cells exposed to hyperosmolarity and cholera toxin. Proceedings of Molecular Biology and Physiology of Water Solute Transport – MIP 2000. 21:15, 2000. 139. Nasser, A., Dietz, J.R., Siddique, M., Antwi, E.K., Perez-Lamboy, G.I., McCormick, M.T., Schocken, D.D., and Vesely, D.L.: Comparison of kaliuretic peptide and atrial natriuretic peptide in the treatment of congestive heart failure. J. Cardiac Failure 6 (Suppl 2):6, 2000.
  • 55. David L. Vesely, M.D., Ph.D. 55 140. Weston, M.W., Vijayangar, R., Overton, R.M., and Vesely, D.L.: Prospective evaluation of left ventricular resection (Batista procedure) utilizing circulating atrial natriuretic peptides and left ventricular ejection fraction. J. Cardiac Failure 6 (Suppl 2):24,2000. 141. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2 microglobulin in congestive heart failure patients. J. Cardiac Failure 6 (Suppl 2):26,2000. 142. Gower, W.R., Jr., Carter, G.M., Shalhub, S., Mcafee, Q., Dietz, J.R., Vesely, D.L., and Fabri, P.J.: Expression of ANP and its receptors by the human carcinoid (BON) cell line. FASEB J 15:A827, 2001. 143. Dietz, J.R., Vesely, D.L., Gower, W.R., Jr., Scott, D.Y., Landon, C.S., and Nazian, S.J.: Neutralization of proANP 1-30 exacerbates hypertension in the spontaneously hypertensive rat (SHR). FASEB J 15:A133, 2001. 144. Vesely, D.L., San Miguel, G.I., Hassan, I., and Schocken, D.D.: Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin releasing hormone, corticotropin, and cortisol. Proc. Of 83rd Annual Meeting of the Endocrine Society (ENDO 2001) 83:299, 2001. 145. Dizon, M.N., and Vesely, D.L.: Gonadotrophin-secreting pituitary tumor associated with hypersecretion of testosterone and hypogonadism after hypophysectomy. Proc. of 83rd Annual Meeting of the Endocrine Society (ENDO 2001) 83:499-500, 2001. 146. Vesely, D.L.: Atrial natriuretic peptides in the new millennium. Proceedings of the European Renal Association Annual Meeting. 50:26, 2001. 147. Vesely, D.L., San Miguel, G.I., Hassan, I., Gower, W.R. Jr., and Schocken, D.D.: Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone and kaliuretic hormone decrease the circulating concentration of thyroxine with reciprocal increase of thyrotropin secreting hormone. J. Cardiac Failure 7:16, 2001. 148. Vesely, D.L., Lawrence, E., Lord, S.T., Leon, Y., McIntyre, P.J., Penix, J., and Grebenev, D.: Tall cell papillary thyroid carcinoma metastatic to femur: Evidence for thyroid hormone synthesis within the femur. Endocrine Practice 7 (Supp. Sept/Oct): 1, 2001. 149. Vesely, D. L., San Miguel, G. I., Hassan, I., Gower, W.R. Jr., and Schocken, D.D.: Four cardiac hormones increase the circulating concentrations of luteinizing hormone and testosterone. Endocrine Practice 7 (Supp. Sept/Oct): 18, 2001. 150. Vesely, D.L., Kanabrocki, E.L., Ryan, M.D., Hermida, R.C., Ayala, D.E., Burden, J., Fabbrini, N., Dawson, S., McCormick, J.B., Bremner, W.F., Third, J.L.H.C.,
  • 56. David L. Vesely, M.D., Ph.D. 56 Shirazi, P., Siegel, G., Nemchausky, N.A., and Hooper, D.C.: Circadian variations in levels of circulating white blood cells in multiple sclerosis patients. Chronobiology Int. 18:1207-1208, 2001. 151. Sawmiller, D.R., Henning, R., Vesely, D.L., and Dehaven, W.: Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart. FASEB 16:A570, 2002. 152. Vesely, D.L.: Diagnosis and treatment with atrial natriuretic peptides of clinical diseases characterized by salt and water retention. Experimental Biology 16:12, 2002. 153. Gower, W.R., Jr., San Miguel, G.I., Hassan, I., Farese, R.V., and Vesely, D.L.: Enhanced atrial natriuretic hormone prohormone gene expression in cardiac and extra-cardiac tissues of type II diabetic Goto-Kakizaki rat. Proc. 28th Annual Meeting of the Clinical Ligand Society 25:257, 2002. (Selected as best abstract at meeting.) 154. Gower, W.R., Jr., San Miguel, G.I., Hassan, I., Farese, R.V., and Vesely, D.L.: Enhanced atrial natriuretic hormone prohormone gene expression in lung, left ventricle of heart and stomach antrum of type II diabetic Goto-Kakizaki rat. Proc. 84th Annual Meeting of the Endocrine Society (ENDO 2002) 84:150, 2002. 155. Song, S., Kamath, S., Vesely, D.L., Mosquera, D., Zigova, T., Sanberg, P., and Sanchez-Ramos, J.: Expression of brain natriuretic peptide by human bone marrow stormal cells. Proc. Soc. Neuroscience 32:4, 2002. 156. Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L.: Atrial natriuretic peptide inhibits the growth of pancreatic adenocarcinoma cells. J. Invest. Med. 51:S623, 2003. 157. Dietz, J.R., Landon, C.S., Nazian, S.J., Vesely, D.L., and Gower, W.R., Jr.: Effects of cardiac hormones on renal excretion and blood pressure in natriuretic peptide receptor A (NPRa) knockout mice. FASEB J 17:A103, 2003. 158. Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L.: Dramatic growth inhibition of human pancreatic adenocarcinoma cells by four cardiac hormones. Proc. 85th Annual Meeting of the Endocrine Society (ENDO 2003) 85:411, 2003. (Selected by The Endocrine Society Publications Committee as one of the best abstracts of meeting and featured as a news article Reuters Health International.) 159. Dietz, J.R., Landon, C.S., Nazian, S.J., Vesely, D.L., and Gower, W.R., Jr.: Effects of cardiac hormones on renal excretion and blood pressure in natriuretic peptide receptor A (NPRa) knockout mice. FASEB J. 18:A299, 2004. 160. Vesely, D.L., Clark, L.C., Garces, A.H., McAfee, Q., Soto, J., and Gower, W.R., Jr.: A cardiovascular hormone inhibits the growth of human pancreatic adenocarcinoma in vivo. Proc. 86th Annual Meeting of the Endocrine Society (ENDO 2004) 86:301, 2004.
  • 57. David L. Vesely, M.D., Ph.D. 57 161. Vesely, D.L. Clark, L.C., Garces, A.H., McAfee, Q.W., Soto, J., and Gower, W.R., Jr.: Four peptide hormones inhibit the growth of human pancreatic adenocarcinomas in vivo. Proc. of 12th International Congress of Endocrinology 12:179, 2004. 162. Dietz, J.R., Landon, C.S., Vesely, D.L., Nazian, S.J., and Gower, W.R., Jr.: Effects of uroguanylin and cyclic GMP (cGMP) on blood pressure and renal excretion in natriuretic peptide A (NPRA) knockout mice. Exp. Biol. 2005/35th International Congress of Physiologic Sciences: 19:A1147, 2005. 163. Vesely, D.L.: Potential treatment of cancer with natriuretic peptides. Exp. Biol. 2005/35th International Congress of Physiologic Sciences: 19:S647, 2005. 164. Vesely, D.L.: Infusion of cardiac natriuretic peptides to treat acute renal failure, congestive heart failure, and cancer. Proceedings of Infusion Nurses Society Annual Meeting 12:1, 2006. (Featured Speaker.) 165. Vesely, D.L.: Cardiac hormones: Dramatic anticancer effects. Proceedings of 9th International Conference on Drug and Gene-Based Therapeutics 9:35, 2006. (Featured Speaker.) 166. Sun, Y., Eichelbaum, E.J., Wang, H., Vesely, D.L.: Insulin and epidermal growth factor’s activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J. Invest. Med. 55(1):S297, 2007 (This Abstract chosen for one of the best Abstracts of the meeting and $500 Award given by Southern Society for Clinical Investigation). 167. Vesely, D.L.: Biology of natriuretic peptide pathway. American Academy of Allergy & Immunology 119:S4812, 2007. (Featured Speaker.) 168. Vesely, D.L., Eichelbaum, E.J., Sun, Y., Abdel, A.A., Vesely, B.A., Luther, S.L., and Gower, W.R., Jr.: Cardiac hormones eliminate up to 80% of human pancreatic adenocarcinomas in athymic mice. Proc. of 89th Annual Meeting of the Endocrine Society (Endo 2007):217, 2007. 169. Vesely, D.L.: Elimination of human cancers growing in athymic mice by natriuretic peptides. FASEB Journal 22:A154, 2008. 170. Vesely, D.L.: Cardiac Hormones for treatment of congestive heart failure, renal failure, and cancer. Distinguished Scientist Award lecture. Proceedings of 34th International Meeting of the Clinical Ligand Society: 34:5, 2008. 171. Vesely, D.L.: Cardiac Hormones for the treatment of cancer. Proceedings of the World Cancer Congress 2008: p 10, 2008. (Keynote Address at World Cancer Congress). 172. Vesely, D.L.: Novel Cardiovascular Hormones. Hormone Research 70 (Suppl 1):10, 2008. (Featured speaker at 47th Annual European Society of Pediatric Endocrinology.)
  • 58. David L. Vesely, M.D., Ph.D. 58 173. Vesely, D.L.: Cardiac Hormones: Magic bullets for the treatment of congestive heart failure, renal failure and cancer. EHRLICH II 2nd World Conference on Magic Bullets (on the 100th Anniversary of Nobel Prize to Paul Erlich), Magic Bullets 2:15, 2008. 174. Vesely, D.L.: Cardiac Hormones: New Anticancer Agents. Anticancer Res. 28:3528-3529, 2008. 175. Vesely, D.L.: Richard A. Kern Award & Lecture – Military Medicine: 114:1, 2008. 176. Vesely, D.L.: Molecular Targets for Cardiovascular Hormones’ Anticancer Effects. Keynote Speaker. The World Cancer Congress, 2:195, 2009. 177. Vesely, D.L.: Four new anticancer drugs: Cardiovascular hormones treatment of human pancreatic, breast, and small-cell lung cancers in athymic mice. International Conference of Drug Discovery and Therapy 2:3, 2010. 178. Lenz, A., Sun, Y., Eichelbaum, E.J., Skelton, W.P. IV, Pi, G., and Vesely, D.L.: Cardiac hormones eliminate some human squamous lung carcinomas in athymic mice. J. Invest. Med. 58:345, 2010.
  • 59. David L. Vesely, M.D., Ph.D. 59 Investigations presented at National and International Scientific Meetings: 1. Vesely, D.L, Castro, A., and Levey, G.S.: Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus. Fifty-eighth Annual Meeting of The Endocrine Society, San Francisco, California, June 23-25, 1976. 2. Lerman, S., Vesely, D.L., Weinstein, R.S., Canterbury, J.M., and Levey, G.S.: Elevated serum parathyroid hormone concentrations in hyperthyroidism. Annual meeting of American Thyroid Association, Toronto, Canada, September 15-18, 1976. 3. Vesely, D.L., Rovere, L.E., and Levey, G.S.: Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosourea. Southern Section of the American Society for Clinical Investigation and the American Federation for Clinical Research, New Orleans, Louisiana, January 27-29, 1977. 4. Vesely, D.L., and Levey, G.S.: Modulation of rat and human guanylate cyclase activity in vitro by chemical carcinogens. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research, Washington, D.C., April 29-May 1, 1977. 5. Vesely, D.L., Graves, W.R., Lo, T.M., Fletcher, M.A., and Levey, G.S.: Isolation of a specific guanylate cyclase inhibitor. Fifty-ninth Annual Meeting of The Endocrine Society, Chicago, Illinois, June 8-10, 1977. 6. Vesely, D.L., Claflin, A.J., Hudson, J.L., Bagwell, C.B., Lehotay, D.C., Lo, T.M., Fletcher, M.A., and Levey, G.S.: The effect of an extract of the balsam pear on the growth and guanylate cyclase activity of an undiffferentiated prostate carcinoma. Southern Section of the American Society for Clinical Investigation and the American Federation for Clinical Research, New Orleans, Louisiana, January 25-29, 1978 (Plenary Session). 7. Monson, T.P., Vesely, D.L., Nolan, C.M., and Straub, K.D.: Pseudomembranous colitis enterotoxin stimulates guanylate cyclase activity. National Meeting of the American Society for Clinical Investigation and the American Society for Clinical Research, Washington, D.C., May 5-7, 1979. 8. Vesely, D.L.: The effect of testosterone, its precursors and metabolites on guanylate cyclase activity. Sixty-first Annual Meeting of The Endocrine Society, Los Angeles, California, June 13-15, 1979. 9. Vesely, D.L.: Growth hormone enhances guanylate cyclase activity. Sixth International meeting of Endocrinology, Melbourne, Australia, February 10–16, 1980. 10. Vesely, D.L.: Human and rat growth hormones enhance guanylate cyclase activity. Sixty-second Annual Meeting of The Endocrine Society, Washington, D.C., June 18-20, 1980. 11. Vesely, D.L.: The interrelationship of streptozotocin, its analogues, and cyclic
  • 60. David L. Vesely, M.D., Ph.D. 60 nucleotide metabolism. International Symposium on Streptozotocin, Washington, D.C., June 21, 1980. 12. Vesely, D.L.: Angiotensinogen, angiotensin I, angiotensin II, and guanylate cyclase activity clarified by SQ 2O, 881. Southern Section of the American Society for Clinical Investigation and the American Federation for Clinical Research, New Orleans, Louisiana, January 15-17, 1981. 13. Stuart, C.A., Furnaletto, R.W., and Vesely, D.L.: Cyclic GMP as the second messenger for somatomedin-C in cartilage. Plenary Session, Southern Section of the American Society for Clinical Investigation and the American Federation for Clinical Research, New Orleans, Louisiana, January 14-16, 1982. 14. Stuart, C.A., Furnaletto, R.W., and Vesely, D.L.: Cyclic nucleotides and somatomedin action in cartilage. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research, Washington, D.C., May 7-10, 1982. 15. Vesely, D.L., Sullivan, N.M., Straub, K.D., Monson, T.P., and Wilkins, T.D.: Clostridium difficile Toxins A and B both enhance guanylate cyclase activity. National Meeting of the American Society for Clinical Investigation and the American Federation of Clinical Research, Washington, D.C., April 29-May 2, 1983. 16. Juan, D., and Vesely, D.L.: 1,25 dihydroxyvitamin D3 is the most potent stimulator of human and rat cortical guanylate cyclase activity in vitro. VIII International Conference on Calcium Regulating Hormones, Kobe, Japan, October 16-24, 1983. 17. Vesely, D.L.: All of the B complex vitamins activate the enzyme guanylate cyclase. National Meeting of the American Society for Clinical Investigation and the American Federation of Clinical Research, Washington, D.C., May 4-7, 1984. 18. Vesely, D.L., Hudson, J.L., Pipkin, J.L., Jr., and Pack, L.D.: Plant growth promoting hormones enhance guanylate cyclase activity. VII International Congress of Endocrinology, Quebec City, Quebec, Canada, July 1-7, 1988. 19. Kemp, S., Elders, M.J., Schedewie, H.K., and Vesely, D.L.: Evidence for a post insulin receptor defect in leprechaunism: decreased cyclic GMP levels and guanylate cyclase activity. Plenary Session, Southern Section of the American Society for Clinical Investigation and the American Federation for Clinical Research, New Orleans, Louisiana, February 5-8, 1986. 20. Sallman, A.L., Bayliss, J.M., and Vesely, D.L.: Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. Southern Section of the American Society for Clinical Investigation and the American Federation for Clinical Research, New Orleans, Louisiana, January 28-30, 1987.
  • 61. David L. Vesely, M.D., Ph.D. 61 21. Vesely, D.L., and Norris, J.S.: Prepro atrial natriuretic factors increase cyclic GMP in isolated smooth muscle cells and aorta. Featured symposia of National Meeting of the American Society for Clinical Investigation and the American Federation of Clinical Research, San Diego, California, May 1-4, 1987. 22. Walters, J.M., Jesperson, R.R., Vesely, D.L., and Baeyens, D.A.: The influence of atrial natriuretic factor on the force of peristaltic contraction and cyclic GMP levels in the small intestine. Arkansas Academy of Sciences, April 3-4, 1987. 23. Sallman, A.L., Bayliss, J.M., and Vesely, D.L.: Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. 10th International Congress of Nephrology, London, England, July 26-31, 1987. 24. Peng, C.F., Murphy, M.L., Nash, A.A., and Vesely, D.L.: Atrial natriuretic factor increases the amplitude of contraction of cultured ventricular myocytes. International Society for Heart Research, Boston, Mass. Sept. 9-12, 1987. 25. Winters, C.J., Baker, B.J., Killingsworth, S., Coter, B.L., Sallman, A.L., Meadows, J., Rico, D.M., and Vesely, D.L.: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate normally in man and increase in congestive heart failure. S.W. Section, Society for Experimental Biology and Medicine, Little Rock, Ark., November 13-14, 1987. 26. Peng, C.F., Murphy, M.L., Nash, A.A., and Vesely, D.L.: Atrial natriuretic factor increases the amplitude of contraction of cultured cardiac myocytes. 60th Annual Meeting of the American Heart Association. Anaheim, California, Nov. 16-19, 1987. 27. Winters, C.J., Sallman, A.L., Meadows, Jr., Rico, D.M., and Vesely, D.L.: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate normally in man and increase in chronic renal failure. Western Society for Clinical Investigation, Carmel, California, February 16-19, 1988. 28. Vesely, D.L., Winters, C.J., Sallman, A.L., Rico, D.M., Meadows, J., LeMay, B., Harris, J., and Melhorn, V.: Circadian variation of prohormone atrial natriuretic factors 1-30, 31-67, and 99-126 in man. Third International Conference on Chronopharmacology, Nice, France, March 14-17, 1988. 29. Winters, C. J., Baker, B.J., Killingsworth, S., Cotter, B.L., Sallman, A.L., Hester, W.L., Rico, D.M., and Vesely, D.L.: The effect of exercise of the plasma concentration of prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 in man. National Meeting of the American Society for Clinical Investigation and the American Federation of Clinical Research, Washington, D.C., April 29-May 2, 1988. 30. Vesely, D.L., Winters, C.J., Sallman, A.L., Hester, W.L., and Rico, D.M.: Circulating prohormone atrial natriuretic peptides 1-30 and 31-67 increase in hyperthyroidism and decrease in hypothyroidism. 70th Annual Meeting of the Endocrine Society, New Orleans, LA, June 8-10, 1988.
  • 62. David L. Vesely, M.D., Ph.D. 62 31. Epstein, M., Loutzenhiser, R., Norsk, P., Winters, C.J. , Rico, D.M., Hester, W.L., Sallman, A.L., and Vesely, D.L.: Responsiveness of prohormone atrial natriuretic peptides 1-30 and 31-67 during immersion-induced hypervolemia in normal humans. Third World Congress on Biologically Active Peptides. New York, N.Y., June 22-26, 1988. 32. Vesely, D.L., Arnold, W.C., Winters, C.J., Sallman, A.L., and Rico, D.M.: Increased circulating concentration of atrial natriuretic factor in persons with pheochromocytomas. Kyoto Symposium on Atrial Natriuretic Peptides, Kyoto, Japan, July 15-16, 1988. 33. Vesely, D.L., Winters, C.J., Sallman, A.L., Meadows, J., Killingsworth, S., Cotter, B.L., Rico, D.M., and Baker, B.J.: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate normally in man and increase in proportion to the severity of the abnormality of salt and water metabolism. 8th International Congress of Endocrinology, Kyoto, Japan, July 17-23, 1988. 34. Ngo, L., Bissett, J.K., Murphy, M.L., Dinh, H., Seth, R.L., Newton, M.T., Hester, W.L., Sallman, A.L., Winters, C.J., and Vesely, D.L.: Increase of prohormone atrial natriuretic peptides 1-30, 31-67, and atrial natriuretic factor with acute myocardial infarction: Peak at day four. Southern Society for Clinical Investigation. New Orleans, LA. Feb. 1-3, 1989. 35. Ngo, L., Wyeth, R., Bissett, J.K., Hester, W.L., Newton, M.T., Rico, D.M., Sallman, A.L., Winters, C.J., and Vesely, D.L.: Release of prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 increases in proportion to right ventricular pacing rate. Southern Society for Clinical Investigation. New Orleans, LA., Feb. 1-3, 1989. 36. Ngo, L., Bissett, J.K., Murphy, M.L., Dinh, H., Seth, R., Wyeth, R.P., Newton, M.T., Hester, W.L., Sallman, A.L., Winters, C.J., and Vesely, D.L.: Increase in prohormone atrial natriuretic peptides 1-30, 31-67 and atrial natriuretic factor in acute myocardial infarction: Peak at day four. 38th Annual Scientific Session of the American College of Cardiology. Anaheim, California, March 19-23, 1989. 37. Rico, D.M., Svendsen, F.J., Huffer, C., Smith, M., Pierce, R., Winters, C.J., and Vesely, D.L.: Increased release of atrial natriuretic factor with increasing atmospheres of pressure in a hyperbaric chamber: Reversal with oxygen therapy. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research, Washington, D.C. April 28-May 1st, 1989. 38. Ngo, L., Bissett, J.K., Murphy, M.L., Dinh, H., Seth, R., Wyeth, R., Sallman, A.L., Rico, D.M., Winters, C.J., and Vesely, D.L.: Acute and sustained release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor with acute myocardial infarction. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research, Washington, D.C. April 28-May 1, 1989. 39. Pevahouse, J.B., Martin, D.R., Trigg, D.J., Winters, C.J., Vesely, D.L., and
  • 63. David L. Vesely, M.D., Ph.D. 63 Buerkert, J.E.: Prohormone atrial natriuretic peptide 31-67 as well as atrial natriuretic factor causes a marked natriuresis. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research, Washington, D.C., April 28-May 1, 1989. 40. Kanabrocki, E. L., Sothern, R. B., Scheving, L. E., Vesely, D. L., Tsai, T. H., Shelstad, J., Greco, J., Bushnell, D. L., Kaplan, E., Rumbyrt, J., Sturtevant, R., Sturtevant, E., Olwin, J. H., and Hrushesky, W.J.M.: Circadian reference data including prohormone atrial natriuretic peptides for men in fifth decade of life. 14th International Conference of the International Society of Chronobiology, Washington, D.C. June 20-24, 1989. 41. McMurray, R.W., Jr. and Vesely, D.L.: Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. 71st Annual Meeting of the Endocrine Society. Seattle, Washington, June 21st-23rd, 1989. 42. Merkouris, R. W., Miller, F.C., Catanzarite, V., Rigg, L.A., Quirk, J. G., Jr., and Vesely, D. L.: Increase in the plasma levels of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor in normal pregnancy. Southern Society for Clinical Investigation. New Orleans, LA. Jan. 17-19, 1990. 43. Kanabrocki, E.L., Sothern, R.B., Olwin, J.H., Bremner, W.F., Bushnell, D.L., Ryan, M., Fabbrini, N., Lammpo, S., Cournover, C., Third, J.L.H.C., Mermall, H., Ferin, H., Vahed, A., Fareed, J., Vesely, D.L., Sackett-Lundeen, L., and Haus, E.: Intrapulmonary administration of heparin in the morning and its effect upon blood variables. Fourth International Conference on Chronopharmacology. Nice, France, March 12-16, 1990. 44. Vesely, D.L., Kanabrocki, E.L., Sothern, R.B., Scheving, L.E., Tsai, T.H., Greco, J., Bushnell, D.L., Kaplan, E., Rumbyrt, J., Sturtevant, R., Sturtevant, F.M., Bremner, W.F., Third, J.L.H.C., Hrushesky, W.J.M., and Olwin, J.H.: Circadian variation of new cardiac hormones that lower blood pressure and increase sodium excretion. Fourth International Conference on Chromopharmacology. Nice, France, March 12-16, 1990. 45. Vesely, D.L., Arnold, W.C., Winters, C.J., Sallman, A.L., and Rico, D.M.: Increased circulating concentrations of the N-terminus and C-terminus of the atrial natriuretic factor prohormone in persons with pheochromocytomas. 72nd Annual Meeting of the Endocrine Society. Atlanta, Georgia, June 20-23, 1990. 46. Godellas, C.V., Fabri, P.J., Gower, W.R., Knierim, T.H., Giordano, A.T., and Vesely, D.L.: Atrial natriuretic factor (ANF) - A new GI peptide hormone. Annual Meeting of the American Assoc. of Endocrine Surgeons, San Jose, California, April 14-16, 1991.
  • 64. David L. Vesely, M.D., Ph.D. 64 47. Baker, B.J., Wu, W.C., Winters, C.J., Dinh, H., Wyeth, R., Sallman, A.L. and Vesely, D.L.: Exercise increases the circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in normal humans. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research. Seattle, Washington, May 3rd - 6th, 1991. 48. Vesely, D.L., Giordano, A.T., and Friedl, F.E.: Atrial natriuretic peptides in invertebrates: Oyster ventricle, auricle, and blood contain all 126 amino acids of the atrial natriuretic factor prohormone. National Meeting of the American Society for Clinical Investigation and the American Federation for Clinical Research. Seattle, Washington, May 3rd - 6th, 1991. 49. McMurray, R.W., Jr., and Vesely, D.L.: Weight reduction decreases the circulating concentration of the N-terminus of the ANF prohormone and blood pressure in obese patients. . 73rd Annual Meeting of the Endocrine Society. Washington, D.C., June 19th - 22nd, 1991. 50. Wyeth R.P., Ackerman B.H., Soulsby, M.E., and Vesely, D.L. Early effects of coronary artery occlusion on the plasma concentration kinectics of natriuretic prohormone N-terminus and C-terminus peptides. Society of Experimental Biology, Houston, Texas, Oct. 8-15, 1991. 51. Saba, S.R., Rameriz, G., Dietz, J.R., and Vesely, D.L.: Immunocytochemical localization of proANF 1-30, proANF 31-67, and atrial natriuretic factor (ANF) in the kidney. Southern Society for Clinical Investigation. New Orleans, LA, Jan. 29-31, 1992. 52. Dietz, J.R., Vesely, D.L., and Nazian, S.J.: A comparison of the effects of atrial natriuretic factor (ANF) and proANF 31-67 on renal excretion and plasma renin activity. Federation of American Societies for Experimental Biology Annual Meeting, Anaheim, CA. April 5-9, 1992. 53. Saba, S.R., Rameriz, G., Dietz, J.R., and Vesely, D.L.: Immunocytochemical localization of proANF 1-30, proANF 31-67, and atrial natriuretic factor (ANF) in human and rat kidney. Plenary session of the American Society for Clinical Investigation. Baltimore, MD. May 1-5, 1992. 54. Vesely, D.L.: Featured Review. Atrial natriuretic peptides: Chronobiological regulation. 5th International Conf. Chronopharmacol. Chronotherapeutics, Amelia Island, FL. July 12-16, 1992. 55. Vesely. D.L. and Giordano, A.T.: Atrial natriuretic peptide hormonal system is present throughout the plant kingdom and increases water flow up stems to flowers. Ninth International Congress of Endocrinology, Nice, France. Aug. 30- Sept. 5, 1992.
  • 65. David L. Vesely, M.D., Ph.D. 65 56. Wyeth, R.P., Soulsby, M.E., Vesely, D.L.: Plasma concentrations of atrial natriuretic prohormone N-terminus peptides during the first hour of acute percutancous occlusion of the left anterior descending coronary artery. Southwestern Section, Society for Experimental Biology and Medicine, Dallas, TX, October 22-24, 1992. 57. Vesely, D.L. Douglas, M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez, G., and Schocken, D.D.: Two peptides from the atrial natriuretic factor prohormone amino terminus produce a significant natriuresis and diuresis in humans. Plenary Session of the American Society for Clinical Investigation, April 30 - May 3rd, 1993, Washington, D.C. 58. Vesely, D.L. Gower, W.R., Jr., Giordano, A.T., and Friedl, F.E.: Molecular species of atrial natriuretic peptides within vertebrate and invertebrate hearts. American Society for Clinical Investigation, Washington, D.C., April 30th - May 3rd, 1993. 59. Vesely, D.L., Gower, W.R., Jr., and Giordano, A.T.: Molecular species of atrial natriuretic peptides within plants: Comparison with molecular species within animal hearts and circulation. 75th Annual Meeting of the Endocrine Society, Las Vegas, Nevada, June 9-12, 1993. 60. Weston, M.W., Cintron, G.B., Giordano, A.T., and Vesely, D.L.: Normalization of atrial natriuretic peptides in cardiac transplant patients. International Society of Cardiovascular Pharmacotherapy, Minneapolis, Minn, August 16-20, 1993. 61. Rodriguez-Paz, G., Vesely, D.L., Douglass, M.A., Dietz, J.R., and Schocken, D.D.: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce adiuresis, natriuresis and/or kaliuresis in humans. This presentation was awarded first place in the Young Investigator Award Competition at the American College of Cardiology, Florida Chapter, 7th Annual Meeting, Orlando, Florida, September 10-12, 1993. 62. Vesely, D.L., Douglass, M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Prohormone atrial natriuretic peptide 79-98 (Kaliuretic stimulator) lowers blood pressure and increase potassium excretion in humans. American Heart Association 66th Annual Meeting, Atlanta, Georgia, November 8-11, 1993. 63. Dietz, J.R., Nazian, S.J., anf Vesely, D.L.: Comparison of intrarenal infusions of atrial natriuretic factor (ANF) and ANF prohormone peptides in the rat. American Soceity of Nephrology Annual Meeting, Dallas, Texas, Nov. 14-17, 1993. 64. Vesely, D.L., Douglass, M.A., Dietz, J.R., Giordano, A.T., McCormick, M.T., Rodriguez-Paz, G. and Schocken, D.D.: Negative feedback of atrial natriuretic peptides. Southern Society from Clinical Investigation Meetings, New Orleans, Feb. 3-5th, 1994. 65. Vesely, D.L.: Overview of atrial natriuretic factor prohormone peptides. Federation Meetings, Anahiem, California, April 24-26th, 1994.
  • 66. David L. Vesely, M.D., Ph.D. 66 66. Dietz, J.R., Vesely, D.L., Gower, W.R., Jr., and Nazian, S.J.: Secretion and renal effects of ANF prohormone peptides. Federation Meetings (Experimental Biology 94), Anahiem, California, April 24-26, 1994. 67. Habibullah, A.A., Villarreal, D., Freeman, H.H., Dietz, J.R., Vesely, D.L., and Simmons, J.C.: Infusion of atrial natriuretic factor prohormone peptides in dogs with experimental heart failure. Federation Meetings (Experimental Biology 94), Anahiem, California, April 24-26, 1994. 68. Friedl, F.E., and Vesely, D.L.: Atrial natriuretic peptides in hemolymph and tissues of the Eastern oyster, Crassostrea virginica. National Shell Fisheries Assoc. Annual Meeting, Charleston, S.C., April 28-30, 1994. 69. Gower, W.R., Jr., Finley, C., Dietz, J., Vesely, D.L., Fabri, P.J., and Chalfont, C.: Expression and regulation of atrial natriuretic peptide mRNA in rat gastrointestinal tract. Am. Gastrointestinal Assoc., New Orleans, LA, May 15-18, 1994. 70. Vesely, D.L., Sothern, R.B., Kanabrocki, E.L., Bremner, F., Third, J.L.A.C., Boles, M.A., Nemchausky, B.M., Olwin, J.H., and Scheving, L.E.: Temporal (circadian) and functional relationships between atrial natriuretic peptides and blood pressure. Biological rhythms and medications: Sixth International Conference of Chronopharmacology and Chronotherapeutics. Amelia Island Plantation, Florida. July 5-9, 1994. 71. Stanek, E.J., Spinler, S.A., Cheng, J.W.M., Charland, S.L., Korbin, S. and Vesely, D.L.: Reduction in circulating atrial natriuretic peptides following intravenous digoxin administration. American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, July 31-August 3, 1994. 72. Poulos, J.E., Phuphanich, S., and Vesely, D.L.: Hypoglycemia secondary to a malignant meningioma. American College of Physicians Annual Meeting, Atlanta, Georgia, March 16-19, 1995. (Selected as one of top 5 clinical cases in United States). 73. Poulos, J.E., Vesely, D.L., Gower, W.R., Jr., and Fontanent, H.: Increased rat atrial natriuretic peptide mRNA synthesis in cirrhosis and congestive heart failure. American College of Physicians Annual Meeting, Atlanta, Georgia, March 16-19, 1995. (Selected as one of top ten research investigations in the United States). 74. Villarreal, D., Habibullah, A.A., Freeman, R.H., Dietz, J.R., Vesely, D.L., and Knoblich, P.: Temporal changes in pro atrial natriuretic factor 31-67 in experimental heart failure. Experimental Biology 95, Atlanta, Georgia, April 9-13, 1995. 75. Habibullah, A.A., Villarreal, D., Freeman, R.H., Dietz, J.R., Vesely, D.L., and Knoblich, P.: Effects of cyclooxygenase inhibition on the renal actions of atrial natriuretic prohormone fragment 31-67 in normal dogs. Experimental Biology
  • 67. David L. Vesely, M.D., Ph.D. 67 95, Atlanta, Georgia, April 9-13, 1995. 76. Chiou, S. and Vesely, D.L.: Kaliuretic peptide: The most potent inhibitor of Na+- K+-ATPase of the atrial natriuretic peptides. American Society for Clinical Investigation Annual Meeting, May 5-8, 1995, San Diego, California. 77. Poulos, J.E., Gower, W.R., Jr., Friedl, F.E., and Vesely, D.L.: Atrial natriuretic peptide gene expression within invertebrate hearts. American Society for Clinical Investigation Annual Meeting, May 5-8, 1995, San Diego, California. 78. Vesely, D.L., Chiou, S., Douglass, M.A., McCormick, M.T., Rodriguez-Paz, G., and Schocken, D.D.: Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. American Society for Clinical Investigation Annual Meeting, May 5-8, 1995, San Diego, California. 79. Vesely, D.L., Norsk, P., Gower, W.R., Jr., Chiou, S., and Epstein, M.: Release of kaliuretic peptide during immersion-induced central hypervolemia in healthy humans. American Society for Clinical Investigation Annual Meeting, May 5-8, 1995, San Diego, California. 80. Gower, W.R., Jr., Finley, C.L., Dietz, J.R., Vesely, D.L., and Fabri, P.J.: Regulation and localization of atrial natriuretic peptide mRNA in rat stomach. 95th Annual Meeting of the American Gastroenterological Association, May 14-17, 1995, San Diego, California. 81. Habibullah, A.A., Villarreal, D., Freeman, R.H., Knoblich, P.R., Dietz, J.R., and Vesely, D.L.: Effects of indomethacin on the renal actions of atrial natriuretic prohormone fragment 31-67 in normal dogs. Midwestern Society of Clinical Investigation, Sept. 28-30, 1995, Chicago, Illinois. 82. Gower, W.R. Jr., Sexton, C., Dietz, J.R., Vesely, D.L., and Fabri, P.J.: Expression and regulation of natriuretic peptide receptor A and B mRNAs in rat stomach. 96th Annual Meeting of the American Gastroenterological Association, May 19-22, 1996, San Francisco, California. 83. Sothern, R.B., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J.L.H.C., McCormick, J.B., Dawson, S., Ryan, M., Greco, J., Bean, J.T., Nemchausky, B.M., Shirazi, P., and Scheving, L.E.: Circadian relationships between circulating atrial natriuretic peptides and serum sodium and chloride in healthy humans. X International Congress of Endocrinology, June 12-15, 1996, San Francisco, California. 84. Marshall, R.M. and Vesely, D.L.: Molecular processing kaliuretic peptide in human plasma and serum. X International Congress of Endocrinology, June 12-15, 1996, San Francisco, California. 85. Yandle, T.G., Vesely, D.L., Hunt, P.J., Espiner, E.A., Richards, A.M., Nicholls, M.G., and Sage, M.: Intracardiac forms of BNP in humans: Evidence for amino terminal BNP formation from pro BNP prior to secretion. X International Congress of Endocrinology, June 12-15, 1996, San Francisco, California.
  • 68. David L. Vesely, M.D., Ph.D. 68 86. Vesely, D.L., Blankenship, M., Douglass, M.A., McCormick, M.T., Rodriguez- Paz, G., and Schocken, D.D.: Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. X International Congress of Endocrinology, June 12-15, 1996, San Francisco, California. 87. Cousins, K.L., Farrell, A.P., Sweeting, R.W., Vesely, D.L., and Keen, J.E.: Release of atrial natriuretic factor prohormone peptides 1-30, 31-67, and 99-126 from perfused hearts of freshwater and seawater acclimated trout. Society of Experimental Biology Osmoregulation Meeting, April 7-10, 1997, Canterbury, England. 88. Daggubati, S., Parks, J.R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Comparison of atrial natriuretic peptide, brain natriuretic peptide, C- natriuretic peptide, adrenomedullin, N-terminal proatrial and probrain natriuretic peptides as indicators of early congestive heart failure. Bio Medicine 97 (American Society for Clinical Investigation) April 25-27, 1997, Washington, D.C. 89. Daggubati, S., Parks, J. R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Vessel Dilator (i.e., proANF 31-67) is the best plasma indicator of mild congestive heart failure (CHF): Comparison with seven other putative peptide markers of CHF. Seventy-ninth Annual Meeting of the Endocrine Society, Minneapolis, Minnesota, June 11 to 14, 1997. (This presentation was chosen for the Endocrine Society's Travel Grant Award). 90. Daggubati, S., Parks, J. R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L.: Comparison of atrial, brain, C-, proatrial and probrain natriuretic peptides, adrenomedullin, endothelin, and neuropeptide Y as indicators of early congestive heart failure. XIX Congress of the European Society of Cardiology, Stockholm, Sweden, August 24-28, 1997. 91. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D.: Vessel dilator stimulates sodium and water diuresis in humans with congestive heart failure. Scientific Meeting of the Heart Failure Society of America, Baltimore, Maryland, Sept. 21-24, 1997. 92. Calderon, E., Anderson, W.McD., Rolfe, M.W., Rumbak, M.J., Overton, R.M., Liu, Z., and Vesely, D.L.: Dexamethasone increases the production of vessel dilator in pulmonary epithelial cells. Am. Lung Assoc. and Am. Thoracic Soc. International Conf. Chicago, IL, April 24-29, 1998. 93. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G. and Schocken, D.D.: Treatment of congestive heart failure with a new natriuretic peptide. XIII World Congress of Cardiology, Rio de Janeiro, Brazil, April 26-30, 1998.
  • 69. David L. Vesely, M.D., Ph.D. 69 94. Stambler, B., Vesely, D.L., Ellenbogen, K., Griffin, J., Wilkoff, B., Keim, S. and Lamas, G.: A prospective comparison of atrial natriuretic factor (ANF) plasma levels in patients randomized to permanent VVIR compared with DDDR pacing mode in the PASE trial. North American Society of Pacing and Electrophysiology 19th Annual Meeting, San Diego, Calif., May 6-8, 1998. 95. Bundy, J.R., Shafii, A.E., Salhab, K.S., Vesely, D.L., Fabri, P.J., Matsui, H., and Gower, W.R. Jr.: Expression of functional natriuretic peptide receptors in rat gastric mucosal (RGM1) cells. American Gastrointestinal Association Annual Meeting. New Orleans, LA, May 16-22, 1998. 96. Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D.: A new cardiac hormone enhances sodium and water diuresis in humans with congestive heart failure. 80th Annual Meeting of the Endocrine Society, New Orleans, LA, June 24-27, 1998. 97. Vesely, D.L.: Vessel dilator in the treatment of congestive heart failure. New Frontiers in Heart Failure Research (Invited speaker), Key Biscayne, Florida, October 30-31, 1998. 98. Bundy, J.R., Yolain, J., Fabri, P.J., Vesely, D.L., and Gower, W.R., Jr.: Localization of ANP receptor subtypes in rat antrum. American Gastrointestinal Association Annual Meeting, Orlando, Florida, May 16-18, 1999. 99. Vesely, D.L., Gower, W.R., Jr., Dietz, J.R., Overton, R.M., Clark, L.C., Antwi, E.K., and Farese, R.V.: Elevated atrial natriuretic peptides and early renal failure in type II diabetic Goto-Kakizaki rats. 81st Annual Meeting of the Endocrine Society, San Diego, California, June 12-15, 1999. 100. Hermida, R.C., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J., Ryan, M., Johnson, M., Shirazi, P., Nemchausky, B.A., and Scheving, L.E.: Circadian variation in serum atrial natriuretic prohormones and blood pressure in aging male subjects. 15th Annual Meeting of the American Society of Hypertension. May 16-20, 2000. 101. Hermida, R.C., Vesely, D.L., Kanabrocki, E.L., Bremner, F.W., Third, J., Ryan, M., Johnson, M., Shirazi, P., Nemchausky, B.A., and Scheving, L.E.: Circadian pattern in serum atrial natriuretic prohormones in relation to blood pressure in aging male subjects. 10th European Meeting on Hypertension, Goteborg, Sweden, May 29 - June 3, 2000. 102. Dizon, M.N., Henry, A.D., Beeson, M., and Vesely, D.L.: Generalized thyroid hormone resistance with possible selective cardiac non-resistance. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000. 103. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator and kaliuretic peptide enhance urinary excretion rate of β2 microglobulin. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 21-24, 2000.
  • 70. David L. Vesely, M.D., Ph.D. 70 104. Jeng, W., Cooper, D.R., Vesely, D.L., and Peguero, A.: Aquaporin-1 and N+, K+ ATPase α expression in human proximal tubule epithelial cells exposed to hyperosmolarity and cholera toxin. Molecular Biology and Physiology of Water Solute Transport – MIP 2000, Goteborg, Sweden, July 1-3, 2000. 105. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of β2 microglobulin in congestive heart failure. 7th World Congress on Heart Failure – Mechanisms and Management, Vancouver, B.C. Canada, July 9-12, 2000. 106. Nasser, A., Dietz, J.R., Siddique, M., Antwi, E.K., Perez-Lamboy, G.I., McCormick, M.T., Schocken, D.D., and Vesely, D.L.: Comparison of kaliuretic peptide and atrial natriuretic peptide in the treatment of congestive heart failure. 4th Annual Scientific Meeting of Heart Failure Society of America, Boca Raton, Florida, September 10-13, 2000. 107. Vesely, D.L., Perez-Lamboy, G.I., and Schocken, D.D.: Long acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2 microglobulin in congestive heart failure patients. 4th Annual Scientific Meeting of Heart Failure Society of America, Boca Raton, Florida, September 10-13, 2000. 108. Weston, M.W., Vijayangar, R., Overton, R.M., and Vesely, D.L.: Prospective evaluation of left ventricular resection (Batista procedure) utilizing circulating atrial natriuretic peptides and left ventricular ejection fraction. 4th Annual Scientific Meeting of Heart Failure Society of America, Boca Raton, Florida, September 10-13, 2000. 109. Gower, W.R., Jr., Carter, G.M., Shalhub, S., Mcafee, Q., Dietz, J.R., Vesely, D.L., and Fabri, P.J.: Expression of ANP and its receptors by the human carcinoid (BON) cell line. Experimental Biology 2001, Orlando, Florida, March 31-April 4, 2001. 110. Dietz, J.R., Vesely, D.L., Gower, W.R., Jr., Scott, D.Y., Landon, C.S., and Nazian, S.J.: Neutralization of proANP 1-30 exacerbates hypertension in the spontaneously hypertensive rat (SHR). Experimental Biology 2001, Orlando, Florida, March 31-April 4, 2001. 111. Dizon, M.N., and Vesely, D.L.: Gonadotrophin-secreting pituitary tumor associated with hypersecretion of testosterone and hypogonadism after hypophysectomy. 83rd Annual Meeting of the Endocrine Society (ENDO 2001), Denver, Colorado, June 20-23, 2001. 112. Vesely, D.L., San Miguel, G.I., Hassan, I., and Schocken, D.D.: Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin releasing hormone, corticotropin, and cortisol. 83rd Annual Meeting of the Endocrine Society (ENDO 2001), Denver, Colorado, June 20-23, 2001. 113. Vesely, D.L.: Plenary Speaker. Atrial natriuretic peptides in the new millennium.
  • 71. David L. Vesely, M.D., Ph.D. 71 European Renal Association Scientific Meeting, Vienna, Austria, June 24-27, 2001. 114. Vesely, D.L., San Miguel, G.I., Hassan, I., Gower, W.R., Jr., and Schocken, D.D.: Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentration of thyroxine with reciprocal increase of thyrotropin secreting hormone. Heart Failure Society of America 5th Scientific Meeting, Washington, DC, September 9-12, 2001. 115. Vesely, D.L., Lawrence, E., Lord, S.T., Leon, Y., McIntyre, P.J., Penix, J., and Grebenev, D.: Tall cell papillary thyroid carcinoma metastatic to femur: Evidence for thyroid hormone synthesis within the femur. 24th Congress of Endocrinology and Metabolism of Turkey Joint Meeting of American Association of Clinical Endocrinologists, Istanbul, Turkey, October 4-6, 2001. 116. Vesely, D. L., San Miguel, G. I., Hassan, I., Gower, W.R. Jr., and Schocken, D.D.: Four cardiac hormones increase the circulating concentrations of luteinizing hormone and testosterone. 24th Congress of Endocrinology and Metabolism of Turkey Joint Meeting of American Association of Clinical Endocrinologists, Istanbul, Turkey, October 4-6, 2001. 117. Vesely, D.L., Kanabrocki, E.L., Ryan, M.D., Hermida, R.C., Ayala, D.E., Burden, J., Fabbrini, N., Dawson, S., McCormick, J.B., Bremner, W.F., Third, J.L.H.C., Shirazi, P., Siegel, G., Nemchausky, N.A., and Hooper, D.C.: Circadian variations in levels of circulating white blood cells in multiple sclerosis patients. 25th International Society of Chronobiology Congress, Antalya, Turkey, October 9-13, 2001. 118. Vesely, D.L.: Diagnosis and treatment with atrial natriuretic peptides of clinical diseases characterized by salt and water retention. Experimental Biology 2002, New Orleans, Louisiana, April 20-24, 2002. 119. Sawmiller, D.R., Henning, R., Vesely, D.L., and Dehaven, W.: Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart. Experimental Biology 2002, New Orleans, Lousiana, April 20-24, 2002. 120. Gower, W.R., Jr., San Miguel, G.I., Hassan, I., Farese, R.V., and Vesely, D.L.: Enhanced atrial natriuretic hormone prohormone gene expression in cardiac and extra-cardiac tissues of type II diabetic Goto-Kakizaki rat. Proc. 28th Annual Meeting of the Clinical Ligand Society, Houston, Texas, May 22-25, 2002. (Selected as best abstract at meeting.) 121. Gower, W.R., Jr., San Miguel, G.I., Hassan, I., Farese, R.V., and Vesely, D.L.: Enhanced atrial natriuretic hormone prohormone gene expression in lung, left ventricle of heart and stomach antrum of type II diabetic Goto-Kakizaki rat. 84th Annual Meeting of the Endocrine Society (ENDO 2002), San Francisco, California, June 19-22, 2002. 122. Song, S., Kamath, S., Vesely, D.L., Mosquera, D., Zigova, T., Sanberg, P., and Sanchez-Ramos, J.: Expression of brain natriuretic peptide by human bone
  • 72. David L. Vesely, M.D., Ph.D. 72 marrow stormal cells. Society for Neuroscience Annual Meeting, Orlando, Florida, November 2-7, 2002. 123. Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L.: Atrial natriuretic peptide inhibits the growth of pancreatic adenocarcinoma cells. Southern Society for Clinical Investigation Meetings, New Orleans, LA, February 20-22, 2003. 124. Dietz, J.R., Landon, C.S., Nazian, S.J., Vesely, D.L., and Gower, W.R., Jr.: Effects of cardiac hormones on renal excretion and blood pressure in natriuretic peptide receptor A (NPRa) knockout mice. Experimental Biology, San Diego, Calif., April 11-15, 2003. 125. Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L.: Dramatic growth inhibition of human pancreatic adenocarcinoma cells by four cardiac hormones. 85th Annual Meeting of the Endocrine Society, Philadelphia, Penn, June 19-22, 2003. 126. Dietz, J.R., Landon, C.S., Nazian, S.J., Vesely, D.L., and Gower, W.R., Jr.: Effects of cardiac hormones on renal excretion and blood pressure in natriuretic peptide receptor A (NPRa) knockout mice. Experimental Biology, Washington DC, April 17-21, 2004. 127. Vesely, D.L., Clark, L.C., Garces, A.H., McAfee, Q., Soto, J., and Gower, W.R., Jr.: A cardiovascular hormone inhibits the growth of human pancreatic adenocarcinoma in vivo. 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16-19, 2004. 128. Vesely, D.L. Clark, L.C., Garces, A.H., McAfee, Q.W., Soto, J., and Gower, W.R., Jr.: Four peptide hormones inhibit the growth of human pancreatic adenocarcinomas in vivo. 12th International Congress of Endocrinology, Lisbon, Portugal. August 31-September 4, 2004. 129. Brian A. Vesely, a sophomore university student, working in Dr. Vesely’s laboratory, won first place with a presentation entitled “Four peptide hormones decrease the number of human breast adenocarcinoma cells” in the Third Annual Undergraduate Research Symposium and Celebration at the University of South Florida, March 31, 2005. 130. Dietz, J.R., Landon, C.S., Vesely, D.L., Nazian, S.J., and Gower, W.R., Jr.: Effects of uroguanylin and cyclic GMP (cGMP) on blood pressure and renal excretion in natriuretic peptide A (NPRA) knockout mice. Exp. Biol. 2005/35th International Congress of Physiological Sciences, San Diego, Calif., March 31- April 5, 2005. 131. Vesely, D.L.: Potential treatment of cancer with natriuretic peptides. Exp. Biol. 2005/35th International Congress of Physiological Sciences, San Diego, Calif., March 31-April 5, 2005.
  • 73. David L. Vesely, M.D., Ph.D. 73 132. Vesely, D.L.: Infusion of cardiac natriuretic peptides to treat acute renal failure, congestive heart failure and cancer. 2006 Infusion Nurses Society Annual Meeting and Industrial Exhibition, Reno, Nevada, May 8-12, 2006. 133. Vesely, D.L.: Cardiac hormones: Dramatic anticancer effects. 9th International Conference on Drug and Gene-Based Therapeutics, Heraklion, Crete, September 2-10, 2006. 134. Sun, Y., Eichelbaum, E.J., Wang, H., Vesely, D.L.: Insulin and epidermal growth factor’s activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. Southern Society for Clinical Investigation Meetings. New Orleans, Louisiana, Feb. 8-10, 2007. 135. Vesely, D.L.: Biology of natriuretic peptide pathway. Annual Meeting of the American Academy of Allergy & Immunology. San Diego, Calif. Feb. 23-28, 2007. 136. Vesely, D.L., Eichelbaum, E.J., Sun, Y., Alli, A.A., Vesely, B.A., Luther, S.L., and Gower, W.R., Jr.: Cardiac hormones eliminate up to 80% of human pancreatic adenocarcinomas in athymic mice. 89th Annual Meeting of the Endocrine Society, Toronto, Canada, June 2-5, 2007. 137. Vesely, D.L.: Elimination of human cancers growing in athymic mice by natriuretic peptides. Experimental Biology 2008 Meeting. San Diego, California. April 5-9, 2008. 138. Vesely, D.L.: Distinguished Scientist Award and lecture. Cardiac Hormones for treatment of congestive heart failure, renal failure, and cancer. 34th International Clinical Ligands Society Annual Meeting, Coral Springs, Florida, June 2-5, 2008. 139. Vesely, D.L.: Keynote Speaker. Cardiac Hormones for the treatment of cancer. The World Cancer Congress 2008: From Basic Research to Therapeutics. Shanghai, China. June 12-17, 2008. 140. Vesely, D.L.: Novel Cardiovascular Hormones. 47th Annual European Society of Pediatric Endocrinology. Istanbul, Turkey. September 20-23, 2008. (Featured Speaker.) 141. Vesely, D.L.: Cardiac Hormones: Magic bullets for the treatment of congestive heart failure, renal failure and cancer. EHRLICH II 2nd World Conference on Magic Bullets (on the 100th Anniversary of Nobel Prize to Paul Erlich), Nurnberg, Germany. Oct. 3-5, 2008. 142. Vesely, D.L.: Cardiac Hormones: New anticancer agents. 8th International Conference of Anticancer Research, Kos, Greece. Oct. 17-22, 2008.
  • 74. David L. Vesely, M.D., Ph.D. 74 143. Vesely, D.L.: Richard A. Kern Award & Lecture: Collaborative Partnerships for the Future: Medical Research Together in the Federal Health Agencies. The114th Annual Meeting of the American Association of Military Surgeons of the United States: San Antonio, Texas, Nov. 9-14, 2008. 144. Vesely, D.L.: Keynote speaker. Molecular Targets for Cardiovascular Hormones’ Anticancer Effects. Keynote Speaker. The World Cancer Congress 2009: Gateway to Future Medicine, Beijing, China, June 21-26, 2009. 145. Vesely, D.L.: Invited Academic Speaker. Four New Anticancer Drugs: Cardiovascular Hormones Treatment of Human Pancreatic, Breast and Small- cell Lung Cancers in Athymic Mice. 2nd International Conference on Drug Discovery and Therapy, Dubai, UAE, Feb. 1-4, 2010. 146. Lenz, A., Sun, Y., Eichelbaum, E.T., Skelton, W.P. IV, Pi, G., and Vesely, D.L.: Cardiac Hormones Eliminate Some Human Squamous Lung Carcinomas in Athymic Mice. Southern Society of Clinical Investigation, New Orleans, LA, Feb. 24-26, 2010.

×